Bannayan-Riley-Ruvalcaba Syndrome

Mendelian MONDO:0007924 Pathograph 27 Show in embeddings browser Autosomal dominant hereditary syndrome Hereditary cancer syndrome PTEN hamartoma tumor syndrome

Bannayan-Riley-Ruvalcaba syndrome (BRRS) is the congenital, pediatric-onset presentation within the PTEN hamartoma tumor syndrome (PHTS) spectrum, caused by heterozygous germline loss-of-function variants in the tumor suppressor PTEN. Loss of PTEN lipid-phosphatase activity removes the brake on phosphatidylinositol-3,4,5-trisphosphate signaling, driving constitutive PI3K/AKT/mTOR activation and disorganized overgrowth of native tissue. The clinical hallmarks are macrocephaly, hamartomatous intestinal polyposis, multiple lipomas, and pigmented macules of the glans penis, usually accompanied by developmental delay, hypotonia, and autism spectrum features. Because BRRS and Cowden syndrome are allelic and can co-occur within a single family carrying one PTEN variant, PTEN-positive BRRS is now managed with the same lifelong cancer surveillance as Cowden syndrome rather than as a benign childhood overgrowth syndrome.

Ask OpenScientist

Ask a research question about Bannayan-Riley-Ruvalcaba Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
7
Pathophys.
17
Phenotypes
3
Hypotheses
2
Gaps
27
Pathograph
2
Genes
7
Medical Actions
1
Subtypes
2
Differentials
1
References
1
Deep Research
👪

Inheritance

1
Autosomal dominant inheritance HP:0000006
BRRS is inherited in an autosomal dominant manner as part of PHTS. Each child of an affected individual has a 50% chance of inheriting the pathogenic PTEN variant.
Autosomal dominant inheritance
Show evidence (3 references)
PMID:20301661 SUPPORT Human Clinical
"PHTS is inherited in an autosomal dominant manner."
GeneReviews states the autosomal dominant inheritance of PHTS, which subsumes BRRS.
PMID:20301661 SUPPORT Human Clinical
"Each child of an affected individual has a 50% chance of inheriting the pathogenic variant and developing PHTS."
GeneReviews gives the 50% transmission risk implied by autosomal dominant inheritance.
PMID:39256443 SUPPORT Human Clinical
"PTEN pathogenic variants in BRRS cases usually demonstrate autosomal dominant inheritance; nevertheless, it is estimated that up to 48% of pathogenic variants can be de novo"
Confirms autosomal dominant inheritance in BRRS specifically and adds the clinically important point that up to 48% of variants arise de novo, so an unremarkable family history does not argue against the diagnosis.
◆

Subtypes

1
10q23 contiguous-gene deletion (PTEN + BMPR1A)
A contiguous-gene deletion at 10q23 removing both PTEN and BMPR1A, combining BRRS features with juvenile polyposis. It was originally described in infantile juvenile polyposis with a severe course, and was hypothesized to reflect a synergistic effect of losing both tumor suppressors. Subsequent series found the phenotype is variable rather than uniformly severe, and severity does not track deletion size. Recognizing this subtype matters practically: it is missed by sequencing alone and requires deletion/duplication testing or chromosomal microarray, and it explains the otherwise puzzling overlap with juvenile polyposis in the differential.
Show evidence (3 references)
PMID:18510548 SUPPORT Human Clinical
"Recently, 10q23 microdeletions involving the PTEN and BMPR1A genes were found in four patients with infantile juvenile polyposis. It was hypothesized that a combined and synergistic effect of the deletion of both genes would explain the condition."
Establishes the contiguous-deletion entity and the original two-gene synergy hypothesis.
PMID:18510548 SUPPORT Human Clinical
"All patients had macrocephaly, dysmorphic features, retardation and congenital abnormalities."
Documents the BRRS-like core (macrocephaly, developmental delay) in deletion carriers. PARTIAL because this is a four-patient series.
PMID:18510548 REFUTE Human Clinical
"No clear correlation was found between ages at onset or severity of gastrointestinal symptoms and the sizes of the deletions."
Recorded as REFUTE against the simple dose/size-severity model: deletion size does not predict severity, which is why this subtype is described as variable rather than uniformly severe.
◈

Mechanistic Hypotheses

3
Canonical PI3K-AKT-mTOR dose-sensitive overgrowth
canonical_pi3k_akt_mtor CANONICAL
Evidence balance 1 support
The default model: PTEN haploinsufficiency raises PIP3, activating PI3K/AKT/mTORC1 and driving growth, survival, and proliferation across lineages. Every BRRS manifestation in this entry is modeled as downstream of this chain unless otherwise grouped.
Pathograph links
PIP3 Accumulation and PI3K-AKT-mTOR Hyperactivation -> Hamartomatous Tissue Overgrowth DIRECT Constitutive growth and survival signaling drives disorganized proliferation of native tissue elements, producing hamartomas. This edge carries two competing explanations: the canonical PIP3/AKT/mTOR route, and an emerging PI3K-independent route via focal adhesion signaling proposed for PTEN-wildtype BRRS.
PIP3 Accumulation and PI3K-AKT-mTOR Hyperactivation -> Neural Progenitor Overgrowth and Brain Enlargement INDIRECT KNOWN INTERMEDIATES mTORC1-driven increases in cell size and progenitor output enlarge the brain.
PIP3 Accumulation and PI3K-AKT-mTOR Hyperactivation -> Synaptic and Circuit Development Dysregulation INDIRECT KNOWN INTERMEDIATES The same signaling excess perturbs synaptic and circuit development, a functional output separable from brain size.
PIP3 Accumulation and PI3K-AKT-mTOR Hyperactivation -> Lifelong Multiorgan Cancer Predisposition INDIRECT KNOWN INTERMEDIATES Sustained proliferative and antiapoptotic signaling in a germline-haploinsufficient background permits second-hit-dependent malignant transformation over decades.
Show evidence (1 reference)
PMID:35594551 SUPPORT Human Clinical
"PTEN hamartoma tumor syndrome (PHTS) is a complex neurodevelopmental disorder characterized by mechanistic target of rapamycin (mTOR) overactivity."
States mTOR overactivity as the accepted molecular characterization of PHTS.
Subcellular localization determines the autism-versus-cancer divergence
pten_nuclear_localization_split EMERGING
Evidence balance 2 support
Proposes that WHERE PTEN is, not only how much of it there is, decides which arm of the phenotype a carrier expresses. PTEN shuttles to the nucleus, and variants that deplete nuclear PTEN while sparing total protein are proposed to segregate with the ASD/macrocephaly presentation rather than the cancer presentation. If correct, this would explain why some PTEN carriers present as neurodevelopmental BRRS and others as adult-onset Cowden cancer risk despite comparable PTEN dosage, and it predicts that localization, not dosage, should stratify surveillance. Evidence is currently confined to the cytoplasmic-predominant Pten mouse; no human genotype-localization-phenotype series exists, which is why this is EMERGING rather than ALTERNATIVE.
Pathograph links
PIP3 Accumulation and PI3K-AKT-mTOR Hyperactivation -> Synaptic and Circuit Development Dysregulation INDIRECT KNOWN INTERMEDIATES The same signaling excess perturbs synaptic and circuit development, a functional output separable from brain size.
PIP3 Accumulation and PI3K-AKT-mTOR Hyperactivation -> Lifelong Multiorgan Cancer Predisposition INDIRECT KNOWN INTERMEDIATES Sustained proliferative and antiapoptotic signaling in a germline-haploinsufficient background permits second-hit-dependent malignant transformation over decades.
Neural Progenitor Overgrowth and Brain Enlargement -> Macrocephaly DIRECT
Synaptic and Circuit Development Dysregulation -> Autism INDIRECT UNKNOWN INTERMEDIATES Autism spectrum characteristics are consistently over-represented in PTEN carriers, but the synaptic intermediates linking mTOR overactivity to the behavioral phenotype remain incompletely defined.
Show evidence (2 references)
PMID:32055008 SUPPORT Model Organism
"To explore the importance of nuclear PTEN in the development of ASD and macrocephaly, we previously generated a mouse model with predominantly cytoplasmic localization of Pten"
States the localization hypothesis and the model built to test it. PARTIAL and MODEL_ORGANISM because the human translational claim is untested.
PMID:24470394 SUPPORT Model Organism
"PTEN Hamartoma Tumor Syndrome (PHTS) is an autosomal-dominant genetic condition underlying a subset of autism spectrum disorder (ASD) with macrocephaly."
Companion model study establishing that disrupting Pten localization alone produces behavioral and glial phenotypes. PARTIAL/MODEL_ORGANISM for the same reason.
PI3K-independent overgrowth via focal adhesion signaling
pi3k_independent_overgrowth EMERGING
Evidence balance 1 support
Proposes a route to the same overgrowth output that does not pass through PIP3/AKT. In PTEN-wildtype classic BRRS, germline TTN variants are enriched, and an edited I-band variant produced loss of contact inhibition associated with focal adhesion kinase changes rather than increased AKT signaling. If real, this would mean mutation-negative BRRS is not simply undetected PTEN disease and may not respond to mTOR-directed therapy the way PTEN-positive disease is presumed to.
Pathograph links
PIP3 Accumulation and PI3K-AKT-mTOR Hyperactivation -> Hamartomatous Tissue Overgrowth DIRECT Constitutive growth and survival signaling drives disorganized proliferation of native tissue elements, producing hamartomas. This edge carries two competing explanations: the canonical PIP3/AKT/mTOR route, and an emerging PI3K-independent route via focal adhesion signaling proposed for PTEN-wildtype BRRS.
Show evidence (1 reference)
PMID:29263846 SUPPORT In Vitro
"suggested lack of contact inhibition in mutant cells"
The functional observation underpinning this hypothesis. PARTIAL/IN_VITRO: an edited cell line, not a demonstration in human tissue.
?

Discussions and Knowledge Gaps

2
What is the actual, prospectively measured cancer risk in individuals ascertained as BRRS in childhood, as opposed to risk inferred from adult, cancer-ascertained Cowden syndrome cohorts?
KNOWLEDGE GAP OPEN gap_brrs_pediatric_ascertained_cancer_risk
Attached to
pathophysiology#Lifelong Multiorgan Cancer Predisposition
The cancer surveillance imposed on children diagnosed with BRRS rests on allelism with Cowden syndrome rather than on direct BRRS-cohort incidence data. The original BRRS delineation explicitly noted that malignancy had not been formally documented in BRRS, and contemporary reviews flag that existing PHTS risk estimates come from strongly ascertained, mostly adult cohorts with an acknowledged absence of pediatric research. If BRRS-ascertained carriers have materially different risk, current pediatric surveillance may be either over- or under-calibrated.
Proposed experiments
Prospective pediatric BRRS cancer-incidence cohort
brrs-prospective-pediatric-cohort
A prospective, multicenter cohort of individuals ascertained in childhood by BRRS clinical criteria and followed into adulthood, reporting age- and site-specific cancer incidence separately for PTEN-positive and PTEN-negative participants.
Show evidence (2 references)
PMID:33140411 SUPPORT Human Clinical
"Although these estimates provide guidance for clinical care, discrepancies between studies, sample sizes, retrospective designs, strongly ascertained cases, and lack of pediatric research emphasizes that data should be interpreted with great caution."
Explicitly identifies the absence of pediatric data and ascertainment bias as the gap.
PMID:31609537 SUPPORT Human Clinical
"We acknowledge the limited understanding of the natural history of childhood-onset PHTS as a cancer predisposition syndrome and present a summary of important management considerations."
A pediatric-focused review stating directly that the natural history of childhood-onset PHTS as a cancer predisposition syndrome is poorly understood.
What explains the roughly 40% of clinically diagnosed BRRS cases with no detectable germline PTEN variant, and do those individuals carry the same cancer risk?
KNOWLEDGE GAP OPEN gap_brrs_mutation_negative_cases
Attached to
pathophysiology#Germline PTEN Loss of Function
Only about 60% of classically ascertained BRRS cases have an identifiable germline PTEN variant, a lower yield than in Cowden syndrome. Several established explanations account for part of the residue and should be excluded before invoking locus heterogeneity: large deletions missed by sequencing (recoverable by MLPA or microarray, as in the 10q23 contiguous-deletion subtype), promoter and deep-intronic variants, somatic mosaicism detectable only in lesional tissue, and germline KLLN promoter hypermethylation, which silences KILLIN from the promoter PTEN and KLLN share while leaving PTEN transcription intact. What remains after all of those is unresolved. Germline TTN missense variants are the leading candidate explanation for part of this residue, but remain a candidate association rather than an established disease-gene relationship. This directly affects management, because the argument for Cowden-equivalent surveillance is anchored on PTEN positivity and does not automatically extend to mutation-negative individuals.
Proposed experiments
Genomic reanalysis of PTEN-mutation-negative BRRS
brrs-mutation-negative-genomics
Genome sequencing with deep-intronic, promoter, structural-variant, and somatic-mosaicism analysis on a cohort of PTEN-mutation-negative clinical BRRS cases, paired with long-term cancer outcome follow-up.
Show evidence (4 references)
PMID:10400993 SUPPORT Human Clinical
"Mutations were identified in 26 of 43 (60%) BRR cases."
Quantifies the incomplete molecular yield that defines this gap.
PMID:10400993 SUPPORT Human Clinical
"Comparisons between BRR and a previously studied group of 37 CS families suggested an increased likelihood of identifying a germline PTEN mutation in families with either CS alone or both CS and BRR when compared with BRR alone"
Documents that BRRS-alone families have a lower PTEN detection rate, sharpening the question of what underlies mutation-negative BRRS.
PMID:21177507 SUPPORT Human Clinical
"We sought to address the hypothesis that germline methylation of the 10q23.31 bidirectional promoter CpG island"
Supports germline KLLN promoter hypermethylation at the shared bidirectional promoter as one established explanation for PTEN-mutation-negative disease.
+ 1 more reference
⚙

Pathophysiology

7
Germline PTEN Loss of Function
A heterozygous germline loss-of-function variant in PTEN at chromosome 10q23 is the initiating lesion. PTEN encodes a dual-specificity phosphatase whose principal physiological substrate is the membrane phospholipid phosphatidylinositol-3,4,5-trisphosphate. Germline PTEN variants are identified in roughly 60% of clinically diagnosed BRRS cases, so a negative test does not exclude the clinical diagnosis.
PTEN hgnc:9588 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves PTEN (hgnc:9588). hgnc:9588 is a gene from the HUGO Gene Nomenclature Committee.
PIP3 3-phosphatase activity GO:0016314 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased PIP3 3-phosphatase activity, annotated with phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase activity (GO:0016314). GO:0016314 is a molecular function from the Gene Ontology. ↓ DECREASED
Downstream
PIP3 Accumulation and PI3K-AKT-mTOR Hyperactivation Loss of PTEN lipid-phosphatase activity leaves PIP3 undephosphorylated, directly releasing downstream PI3K/AKT/mTOR signaling from negative regulation.
Show evidence (3 references)
PMID:10400993 SUPPORT Human Clinical
"PTEN maps to 10q23 and encodes a dual specificity phosphatase, a substrate of which is phosphatidylinositol 3,4,5-triphosphate, a phospholipid in the phosphatidylinositol 3-kinase pathway."
Establishes the gene location and the molecular identity of PTEN as the phosphatase acting on PIP3, the substrate whose dephosphorylation is lost in BRRS.
PMID:10400993 SUPPORT Human Clinical
"Mutations were identified in 26 of 43 (60%) BRR cases."
Quantifies the germline PTEN detection rate in a dedicated BRRS cohort, supporting both the causal gene assignment and the incomplete molecular yield.
PMID:9352843 SUPPORT Human Clinical
"The three hamartomatous polyposis syndromes, Bannayan-Riley-Ruvalcaba syndrome, juvenile polyposis coli, and Cowden disease, may share the same genetic defect because of their common map localization to chromosome 10q23."
The original positional mapping study that localized the BRRS locus to 10q23, the interval subsequently shown to contain PTEN.
PIP3 Accumulation and PI3K-AKT-mTOR Hyperactivation
With PTEN-mediated dephosphorylation lost, PIP3 accumulates at the plasma membrane and recruits AKT, producing constitutive PI3K/AKT/mTOR signaling. The resulting mTOR overactivity increases cell growth, protein synthesis, and survival signaling across many lineages and is the shared molecular engine of every downstream BRRS manifestation. This node is also the pharmacological rationale for mTOR-inhibitor trials in PHTS.
Canonical PI3K-AKT-mTOR dose-sensitive overgrowth PI3K-independent overgrowth via focal adhesion signaling Subcellular localization determines the autism-versus-cancer divergence
PI3K/AKT signaling GO:0043491 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased PI3K/AKT signaling, annotated with phosphatidylinositol 3-kinase/protein kinase B signal transduction (GO:0043491). GO:0043491 is a biological process from the Gene Ontology. ↑ INCREASED mTOR signaling GO:0031929 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased mTOR signaling, annotated with TOR signaling (GO:0031929). GO:0031929 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Hamartomatous Tissue Overgrowth Constitutive growth and survival signaling drives disorganized proliferation of native tissue elements, producing hamartomas. This edge carries two competing explanations: the canonical PIP3/AKT/mTOR route, and an emerging PI3K-independent route via focal adhesion signaling proposed for PTEN-wildtype BRRS. Canonical PI3K-AKT-mTOR dose-sensitive overgrowth PI3K-independent overgrowth via focal adhesion signaling
Neural Progenitor Overgrowth and Brain Enlargement mTORC1-driven increases in cell size and progenitor output enlarge the brain. Canonical PI3K-AKT-mTOR dose-sensitive overgrowth
Synaptic and Circuit Development Dysregulation The same signaling excess perturbs synaptic and circuit development, a functional output separable from brain size. Canonical PI3K-AKT-mTOR dose-sensitive overgrowth Subcellular localization determines the autism-versus-cancer divergence
Lifelong Multiorgan Cancer Predisposition Sustained proliferative and antiapoptotic signaling in a germline-haploinsufficient background permits second-hit-dependent malignant transformation over decades. Canonical PI3K-AKT-mTOR dose-sensitive overgrowth Subcellular localization determines the autism-versus-cancer divergence
Penile freckling Genital lentiginosis is a highly specific BRRS sign attributed to PTEN-driven melanocytic dysregulation, but the intermediate steps linking PI3K/AKT/mTOR activation to focal glans pigmentation are not established.
Show evidence (1 reference)
PMID:35594551 SUPPORT Human Clinical
"PTEN hamartoma tumor syndrome (PHTS) is a complex neurodevelopmental disorder characterized by mechanistic target of rapamycin (mTOR) overactivity."
States mTOR overactivity as the defining molecular consequence of germline PTEN loss in PHTS, the mechanism this node models.
Hamartomatous Tissue Overgrowth
Unrestrained growth signaling produces hamartomas: benign, disorganized overgrowths composed of cell types native to the tissue of origin. In BRRS this is expressed predominantly as hamartomatous polyps distributed throughout the gastrointestinal tract, subcutaneous and visceral lipomas, and vascular lesions, and it is the substrate for the syndrome's structural burden in childhood.
adipocyte CL:0000136 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves adipocyte (CL:0000136). CL:0000136 is a cell type from the Cell Ontology. intestinal epithelial cell CL:0002563 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves intestinal epithelial cell (CL:0002563). CL:0002563 is a cell type from the Cell Ontology. endothelial cell CL:0000115 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves endothelial cell (CL:0000115). CL:0000115 is a cell type from the Cell Ontology.
cell proliferation GO:0008283 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased cell proliferation, annotated with cell population proliferation (GO:0008283). GO:0008283 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Hamartomatous polyposis
Lipoma
Hemangioma
PTEN Hamartoma of Soft Tissue Formation The overgrowth program produces the distinctive intramuscular mesenchymal lesion of PHTS, combining ectopic fat with malformed fast-flow vessels.
Show evidence (2 references)
PMID:9352843 SUPPORT Human Clinical
"Bannayan-Riley-Ruvalcaba syndrome is a congenital syndrome with characteristic features of macrocephaly, cognitive and motor dysfunction, subcutaneous and visceral lipomas and hemangiomas, and intestinal juvenile polyposis."
Enumerates the hamartomatous tissue lesions (lipomas, hemangiomas, intestinal polyposis) that constitute this overgrowth node in BRRS.
PMID:20301661 SUPPORT Human Clinical
"BRRS is a congenital disorder characterized by macrocephaly, intestinal hamartomatous polyposis, lipomas, and pigmented macules of the glans penis."
The GeneReviews definition of BRRS, confirming hamartomatous polyposis and lipomas as defining tissue-level manifestations.
PTEN Hamartoma of Soft Tissue Formation
The distal, lesion-level node of the overgrowth arm. PTEN hamartoma of soft tissue (PHOST) is a distinctive, predominantly intramuscular lesion of PHTS: a disorganized overgrowth of mesenchymal elements combining ectopic adipose tissue, fibrous tissue, and malformed fast-flow vascular channels. It is radiologically mistaken for a simple arteriovenous malformation but is histologically distinct, and it is the lesion that drives pain, swelling, and functional loss in BRRS. It is the specific target of sirolimus therapy in this entry.
adipocyte CL:0000136 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves adipocyte (CL:0000136). CL:0000136 is a cell type from the Cell Ontology. endothelial cell CL:0000115 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves endothelial cell (CL:0000115). CL:0000115 is a cell type from the Cell Ontology. fibroblast CL:0000057 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves fibroblast (CL:0000057). CL:0000057 is a cell type from the Cell Ontology.
Downstream
Arteriovenous malformation PHOST is the lesion most often reported clinically as an arteriovenous malformation in BRRS, which is the phenotype term this entry binds.
Show evidence (4 references)
PMID:22446940 SUPPORT Human Clinical
"We designate this disorganized overgrowth of essentially mesenchymal elements as PTEN hamartoma of soft tissue."
The defining pathological description of PHOST, establishing this node as a distinct lesion entity rather than a generic vascular malformation.
PMID:22446940 SUPPORT Human Clinical
"Lesions manifested by 15 years of age, normally with pain and swelling, and were most often located in the lower extremity."
Establishes the pediatric onset and the clinical burden (pain, swelling) that makes this node the target of lesion-directed therapy in BRRS.
PMID:17526801 SUPPORT Human Clinical
"Vascular anomalies were found in 14/26 (54%) of patients: 8/14 (57%) had multiple lesions and 11/13 (85%) who had cross-sectional imaging had intramuscular vascular lesions."
Quantifies frequency and the characteristic intramuscular location in a PTEN-mutation cohort.
+ 1 more reference
Neural Progenitor Overgrowth and Brain Enlargement
The structural arm of PTEN loss in the nervous system. PTEN is a strong negative regulator of growth in neural lineages, so mTORC1-driven increases in cell size and progenitor output enlarge the brain. Clinically this is marked macrocephaly, typically evident from infancy and non-progressive after early childhood, and it is megalencephaly rather than hydrocephalus.
Subcellular localization determines the autism-versus-cancer divergence
neural progenitor cell CL:0011020 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neural progenitor cell (CL:0011020). CL:0011020 is a cell type from the Cell Ontology.
neurogenesis GO:0022008 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased neurogenesis (GO:0022008). GO:0022008 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Macrocephaly Subcellular localization determines the autism-versus-cancer divergence
Show evidence (2 references)
PMID:32055008 SUPPORT Model Organism
"predominant Pten localization results in a phenotype of extreme macrocephaly and autistic-like traits"
Mouse model showing that perturbing Pten produces brain overgrowth. Typed MODEL_ORGANISM; the human macrocephaly phenotype itself is separately supported by human clinical evidence on the Macrocephaly phenotype entry.
PMID:31609537 SUPPORT Human Clinical
"PTEN hamartoma tumor syndrome (PHTS) is a highly variable autosomal dominant condition associated with intellectual disability, overgrowth, and tumor predisposition phenotypes, which often overlap."
Human review linking PHTS to an overgrowth phenotype, the output of this node.
Synaptic and Circuit Development Dysregulation
The functional arm of PTEN loss in the nervous system, distinct from and not reducible to brain size. Disrupted synaptic and circuit development manifests as hypotonia, delayed motor milestones, global developmental delay, intellectual disability, and autism spectrum characteristics. Neonatal or infantile onset and delayed motor development are among the features that historically distinguished BRRS from adult-presenting Cowden syndrome. Candidate cellular intermediates include microglial activation with excessive synaptic pruning, demonstrated in the cytoplasmic-predominant Pten mouse but not yet confirmed in human tissue.
Subcellular localization determines the autism-versus-cancer divergence
neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
neuron differentiation GO:0030182 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal neuron differentiation (GO:0030182). GO:0030182 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Downstream
Global developmental delay
Autism Autism spectrum characteristics are consistently over-represented in PTEN carriers, but the synaptic intermediates linking mTOR overactivity to the behavioral phenotype remain incompletely defined. Subcellular localization determines the autism-versus-cancer divergence
Intellectual disability
Hypotonia
Show evidence (3 references)
PMID:10400993 SUPPORT Human Clinical
"Pigmented macules of the glans penis, delayed motor development and neonatal or infant onset are noted only in BRR."
Identifies delayed motor development and congenital/infantile onset as BRRS-restricted features, supporting this functional arm and its early timing.
PMID:34983360 SUPPORT Human Clinical
"Intellectual disability and developmental delay (global, motor and speech and language) were also reported frequently."
Human systematic review establishing the functional neurodevelopmental outputs modeled by this node, independent of head size.
PMID:32055008 SUPPORT Model Organism
"We found increased Iba1 and C1q expression with enhanced phagocytic capacity in Ptenm3m4/m3m4 microglia, indicating microglial activation."
Proposes microglial activation and excessive synaptic pruning as the cellular intermediate. PARTIAL and MODEL_ORGANISM because this is a mouse result not confirmed in human tissue.
Lifelong Multiorgan Cancer Predisposition
Because every cell carries one inactivated PTEN allele, somatic loss of the second allele in a susceptible tissue removes tumor-suppressor function entirely and permits malignant transformation. The resulting lifetime risks span breast, thyroid, endometrial, renal, colorectal, and cutaneous melanocytic malignancy. This node carries the central nosological insight of the entry: although malignancy was not formally documented in the original BRRS descriptions, PTEN-positive BRRS and Cowden syndrome are allelic presentations of one disorder and therefore warrant identical cancer surveillance. Cancer risk in BRRS is largely realized in adulthood, so the childhood diagnosis obligates lifelong follow-up rather than pediatric oncologic treatment.
thyroid follicular cell CL:0002258 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves thyroid follicular cell (CL:0002258). CL:0002258 is a cell type from the Cell Ontology. epithelial cell CL:0000066 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves epithelial cell (CL:0000066). CL:0000066 is a cell type from the Cell Ontology.
negative regulation of apoptosis GO:0043066 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased negative regulation of apoptosis, annotated with negative regulation of apoptotic process (GO:0043066). GO:0043066 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Breast carcinoma
Thyroid carcinoma
Endometrial carcinoma
Renal cell carcinoma
Colon cancer
Melanoma
Hashimoto thyroiditis Benign thyroid pathology including Hashimoto thyroiditis is over-represented in BRRS; the autoimmune intermediates are not modeled here.
Show evidence (5 references)
PMID:10400993 SUPPORT Human Clinical
"Thus, PTEN mutation-positive CS and BRR may be different presentations of a single syndrome and, hence, both should receive equal attention with respect to cancer surveillance."
The key conclusion establishing that PTEN-positive BRRS carries the Cowden-equivalent cancer burden and must be surveilled accordingly.
PMID:10400993 NO_EVIDENCE Human Clinical
"CS is characterized by multiple hamartomas and an increased risk of benign and malignant disease of the breast, thyroid and central nervous system, whilst the presence of cancer has not been formally documented in BRR."
Recorded as NO_EVIDENCE because it asserts an absence of evidence rather than supporting or refuting the node: malignancy had not been formally established in BRRS-ascertained cohorts. It is retained to make explicit that the cancer risk attributed to BRRS is inferred from allelism with Cowden syndrome rather than from direct BRRS-cohort incidence data.
PMID:22252256 SUPPORT Human Clinical
"Lifetime risks for a variety of cancers, now extending to colorectal cancer, kidney cancer, and melanoma, are increased in patients with PTEN mutations."
The prospective PHTS cohort establishing that germline PTEN carriers, the molecular class to which PTEN-positive BRRS belongs, carry elevated multiorgan cancer risk.
+ 2 more references
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Bannayan-Riley-Ruvalcaba Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

17
Breast 1
Breast carcinoma HP:0003002 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Breast carcinoma (HP:0003002). HP:0003002 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
PMID:20301661 SUPPORT Human Clinical
"The lifetime risk of developing breast cancer is 85%, with an average age of diagnosis between 38 and 46 years."
GeneReviews gives the lifetime breast cancer risk and the adult age range at which it is realized.
PMID:22252256 SUPPORT Human Clinical
"Estimated lifetime risks were, respectively, 85.2% (95% CI, 71.4%-99.1%), 35.2% (19.7%-50.7%), 28.2% (17.1%-39.3%), 9.0% (3.8%-14.1%), 33.6% (10.4%-56.9%), and 6% (1.6%-9.4%)."
Prospective PHTS cohort reporting the 85.2% lifetime breast cancer risk, the first value in the ordered list of breast, thyroid, endometrium, colorectum, kidney, and melanoma.
PMID:33140411 SUPPORT Human Clinical
"The tumor spectrum included female breast cancer (CLTRs including sex-specific estimates at age 60-70: 67% to 85%), endometrium cancer (19% to 28%), thyroid cancer (6% to 38%), renal cancer (2% to 24%), colorectal cancer (9% to 32%), and melanoma (0% to 6%)."
Gives the cross-cohort ranges for every cancer site curated in this entry, which is why the descriptions frame risk as a range rather than a single point estimate.
Cardiovascular 2
Hemangioma HP:0001028 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hemangioma (HP:0001028). HP:0001028 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:9352843 SUPPORT Human Clinical
"Bannayan-Riley-Ruvalcaba syndrome is a congenital syndrome with characteristic features of macrocephaly, cognitive and motor dysfunction, subcutaneous and visceral lipomas and hemangiomas, and intestinal juvenile polyposis."
Names subcutaneous and visceral hemangiomas among the characteristic BRRS features.
Arteriovenous malformation HP:0100026 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Arteriovenous malformation (HP:0100026). HP:0100026 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
PMID:39256443 SUPPORT Human Clinical
"Another frequent finding was vascular abnormalities, namely, hemangiomas (8/33) and AVMs (6/33)."
Names arteriovenous malformations specifically (not merely "vascular malformations") and gives the BRRS report-level frequency, 6 of 33.
PMID:39256443 SUPPORT Human Clinical
"Notably, AVMs can occur in the CNS and carry a potential risk of bleeding and complications related to mass effects"
Supports the clinical significance of AVMs in BRRS, including the CNS location that drives imaging and intervention decisions.
PMID:10400993 SUPPORT Human Clinical
"Additional features observed in BRR, which may also occur in a minority of CS patients, include Hashimoto's thyroiditis, vascular malformations and mental retardation."
Recorded as PARTIAL because this source establishes vascular malformations broadly as a BRRS feature but does not specify the arteriovenous subtype that this phenotype is bound to.
Digestive 2
Hamartomatous polyposis HP:0004390 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hamartomatous polyposis (HP:0004390). HP:0004390 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
PMID:20301661 SUPPORT Human Clinical
"BRRS is a congenital disorder characterized by macrocephaly, intestinal hamartomatous polyposis, lipomas, and pigmented macules of the glans penis."
GeneReviews names intestinal hamartomatous polyposis as a defining BRRS feature.
PMID:34754688 SUPPORT Human Clinical
"The esophagogastroduodenoscopy (EGD) and colonoscopy revealed an erosive gastric mucosa as well as numerous polyps throughout the gastrointestinal tract."
A BRRS case report documenting polyp distribution across both upper and lower gastrointestinal tract, supporting the diffuse rather than colon-restricted pattern.
PMID:22672595 SUPPORT Human Clinical
"The cumulative risk of developing benign gastrointestinal polyps was 70% at age 60."
Multinational PTEN-carrier cohort quantifying the cumulative burden of benign gastrointestinal polyps.
Colon cancer HP:0003003 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Colorectal carcinoma, annotated with Colon cancer (HP:0003003). HP:0003003 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:22672595 SUPPORT Human Clinical
"Benign gastrointestinal lesions are common in PTEN mutation carriers, and a three- to four-fold increased lifetime risk of colorectal cancer compared with the general population may exist."
Multinational PTEN-carrier cohort quantifying the relative colorectal cancer risk that justifies colonoscopic surveillance.
Endocrine 1
Thyroid carcinoma HP:0002890 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Thyroid carcinoma (HP:0002890). HP:0002890 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:20301661 SUPPORT Human Clinical
"The lifetime risk for thyroid cancer (usually follicular, rarely papillary, but never medullary thyroid cancer) is approximately 35%."
GeneReviews gives the thyroid cancer lifetime risk and its histologic pattern.
PMID:20301661 SUPPORT Human Clinical
"Yearly thyroid ultrasound from the time of diagnosis (earliest reported at age 7 years) and skin check with physical examination."
Supports the childhood onset of thyroid malignancy risk, with the earliest reported case at age 7, motivating pediatric thyroid surveillance.
Genitourinary 1
Endometrial carcinoma HP:0012114 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Endometrial carcinoma (HP:0012114). HP:0012114 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301661 SUPPORT Human Clinical
"The risk for endometrial cancer may approach 28%."
GeneReviews gives the endometrial cancer lifetime risk estimate.
Head and Neck 1
Macrocephaly VERY_FREQUENT HP:0000256 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Macrocephaly (HP:0000256). HP:0000256 is a phenotype from the Human Phenotype Ontology.
Show evidence (4 references)
PMID:20301661 SUPPORT Human Clinical
"BRRS is a congenital disorder characterized by macrocephaly, intestinal hamartomatous polyposis, lipomas, and pigmented macules of the glans penis."
GeneReviews names macrocephaly as a defining feature of BRRS.
PMID:28526761 SUPPORT Human Clinical
"Macrocephaly (average head circumference of + 5.7 SD) with developmental delay, ID and/or ASD were the most common presenting signs/symptoms (66 %)."
Supports the disease-phenotype association and quantifies the severity of macrocephaly in pediatric PHTS (mean head circumference +5.7 SD). Note this 66% figure is a composite presenting-symptom statistic (macrocephaly together with developmental delay, ID and/or ASD), not a macrocephaly frequency, so it is not used to set the frequency band.
PMID:39256443 SUPPORT Human Clinical
"Macrocephaly was described in almost all case reports (32/33)."
The evidence anchoring the VERY_FREQUENT band: macrocephaly reported in 32 of 33 BRRS case reports (97%), within the 80-100% range.
+ 1 more reference
Musculoskeletal 2
Lipoma HP:0012032 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Lipoma (HP:0012032). HP:0012032 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
PMID:10400993 SUPPORT Human Clinical
"The partial clinical overlap in these two syndromes is exemplified by the hallmark features of BRR: macrocephaly and multiple lipomas, the latter of which occur in a minority of individuals with CS."
Identifies multiple lipomas as a hallmark BRRS feature that discriminates it from Cowden syndrome, where lipomas are a minority finding.
PMID:10400993 SUPPORT Human Clinical
"Additionally, the presence of lipomas was correlated with the presence of PTEN mutation in BRR patients"
Documents the genotype-phenotype correlation between lipomas and a detectable PTEN variant within BRRS.
PMID:39256443 SUPPORT Human Clinical
"Lipomas were mentioned in more than half of the cases (18/33), and the second most common lesion was gastrointestinal polyps (16/33)."
BRRS-specific frequency for lipomas from the pediatric systematic review, and the companion figure for gastrointestinal polyps.
Hypotonia HP:0001252 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypotonia (HP:0001252). HP:0001252 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
PMID:29263846 SUPPORT Human Clinical
"Muscle weakness and hypotonia cause affected BRRS infants to appear"
Names hypotonia explicitly in BRRS infants and links it to the delayed motor development curated in this entry.
PMID:39256443 SUPPORT Human Clinical
"some PTEN pathogenic variant carriers can suffer from muscle hypotonia, which is associated with motor delay"
BRRS systematic review naming muscle hypotonia and its association with motor delay. The hedged wording ("some") is why no frequency band is asserted.
PMID:9352843 SUPPORT Human Clinical
"Bannayan-Riley-Ruvalcaba syndrome is a congenital syndrome with characteristic features of macrocephaly, cognitive and motor dysfunction, subcutaneous and visceral lipomas and hemangiomas, and intestinal juvenile polyposis."
Recorded as PARTIAL because the source documents motor dysfunction as a core BRRS feature without naming hypotonia specifically; it supports the motor-impairment phenotype but does not by itself establish the tone abnormality.
Nervous System 3
Global developmental delay HP:0001263 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Global developmental delay (HP:0001263). HP:0001263 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:28526761 SUPPORT Human Clinical
"Macrocephaly (average head circumference of + 5.7 SD) with developmental delay, ID and/or ASD were the most common presenting signs/symptoms (66 %)."
Establishes developmental delay as part of the leading presentation in a pediatric PHTS cohort.
PMID:34983360 SUPPORT Human Clinical
"Intellectual disability and developmental delay (global, motor and speech and language) were also reported frequently."
Systematic review confirming that global, motor, and speech-language delay are frequent in constitutional PTEN variant carriers.
Autism OCCASIONAL HP:0000717 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Autism spectrum characteristics, annotated with Autism (HP:0000717). HP:0000717 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:34983360 SUPPORT Human Clinical
"Meta-analysis using a random effects model estimated pooled prevalence of ASD characteristics at 25% (95% CI 16-33%), although this should be interpreted cautiously due to possible biases in existing literature."
Provides the quantitative pooled prevalence (25%) that sets the OCCASIONAL band (5-29%). Documenting a deliberate band choice: single cohorts report higher figures that would fall in FREQUENT (the pediatric PHTS chart review cited below reports 50% ASD diagnoses), but the pooled random-effects estimate across 14 studies is preferred here as the less ascertainment-biased summary, and its confidence interval of 16-33% sits mostly within OCCASIONAL.
PMID:28526761 SUPPORT Human Clinical
"It is recognised that 5% - 10 % of children with macrocephaly and autism spectrum disorder (ASD) and/or intellectual disability (ID) have a heterozygous pathogenic mutation in the PTEN tumour suppressor gene that is associated with PTEN hamartoma tumour syndrome."
Supports the reciprocal clinical rule that macrocephaly plus ASD should prompt PTEN testing.
Intellectual disability HP:0001249 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Intellectual disability (HP:0001249). HP:0001249 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:10400993 SUPPORT Human Clinical
"Additional features observed in BRR, which may also occur in a minority of CS patients, include Hashimoto's thyroiditis, vascular malformations and mental retardation."
Documents cognitive impairment (reported using the era's terminology) as a recognized BRRS feature.
PMID:34983360 SUPPORT Human Clinical
"Intellectual disability and developmental delay (global, motor and speech and language) were also reported frequently."
Systematic review confirming intellectual disability is frequently reported in PTEN carriers.
Other 4
Penile freckling HP:0031447 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pigmented macules of the glans penis, annotated with Penile freckling (HP:0031447). HP:0031447 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
PMID:20301661 SUPPORT Human Clinical
"BRRS is a congenital disorder characterized by macrocephaly, intestinal hamartomatous polyposis, lipomas, and pigmented macules of the glans penis."
GeneReviews names pigmented macules of the glans penis as a defining BRRS feature.
PMID:10400993 SUPPORT Human Clinical
"Pigmented macules of the glans penis, delayed motor development and neonatal or infant onset are noted only in BRR."
Directly supports the diagnostic specificity claim: this sign is restricted to BRRS within the PHTS spectrum.
PMID:39256443 SUPPORT Human Clinical
"Pigmented penile macules were described in the majority of male reports (21/28)."
BRRS-specific frequency in male cases. Note this sign is sex-limited, which is also why the same review found a male predominance among published cases; no whole-cohort frequency band is asserted here for that reason.
Hashimoto thyroiditis HP:0000872 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hashimoto thyroiditis (HP:0000872). HP:0000872 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:10400993 SUPPORT Human Clinical
"Additional features observed in BRR, which may also occur in a minority of CS patients, include Hashimoto's thyroiditis, vascular malformations and mental retardation."
Documents Hashimoto thyroiditis as a recognized BRRS feature.
PMID:28526761 SUPPORT Human Clinical
"Clinical features included dermatological findings (66 %), gastrointestinal (GI) symptoms (34 %), ASD diagnosis (50 %), abnormal brain imaging (53 % of those examined) and abnormal thyroid imaging (26 %)."
Recorded as PARTIAL because abnormal thyroid imaging in 26% of a pediatric PHTS cohort establishes that thyroid involvement is already present in childhood, but does not itself establish autoimmune thyroiditis as the pathology.
Renal cell carcinoma HP:0005584 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Renal cell carcinoma (HP:0005584). HP:0005584 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301661 SUPPORT Human Clinical
"The lifetime risk for renal cell cancer (predominantly of papillary histology) is 34%."
GeneReviews gives the renal cell carcinoma lifetime risk and histologic pattern.
Melanoma HP:0002861 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Melanoma (HP:0002861). HP:0002861 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:22252256 SUPPORT Human Clinical
"Lifetime risks for a variety of cancers, now extending to colorectal cancer, kidney cancer, and melanoma, are increased in patients with PTEN mutations."
Establishes melanoma as part of the confirmed germline PTEN cancer spectrum in a prospective cohort.
🧬

Genetic Associations

2
PTEN
Gene: PTEN hgnc:9588 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is PTEN (hgnc:9588). hgnc:9588 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (4 references)
PMID:34754688 SUPPORT Human Clinical
"Bannayan-Riley-Ruvalcaba syndrome (BRRS) is a rare genetic disorder caused by germline mutations in the phosphatase and tensin homolog (PTEN) gene."
Directly assigns germline PTEN variants as the cause of BRRS.
PMID:10400993 SUPPORT Human Clinical
"Mutations were identified in 26 of 43 (60%) BRR cases."
Establishes the approximately 60% germline PTEN detection rate in a dedicated BRRS cohort.
PMID:10400993 SUPPORT Human Clinical
"Among CS, BRR and BRR/CS overlap families that are PTEN mutation positive, the mutation spectra appear similar."
Supports the claim that the BRRS mutation spectrum is not distinguishable from that of Cowden syndrome.
+ 1 more reference
TTN
Gene: TTN hgnc:12403 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is TTN (hgnc:12403). hgnc:12403 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE
Show evidence (3 references)
PMID:29263846 SUPPORT Human Clinical
"We exome-sequenced 35 unrelated PTEN-wildtype patients with classic presentation of BRRS and identified TTN germline missense variants in 12/35 (34%) patients."
The primary human genetic observation: rare TTN missense variants in about a third of PTEN-wildtype classic BRRS patients.
PMID:29263846 SUPPORT In Vitro
"suggested lack of contact inhibition in mutant cells"
Cell-based functional support for one TTN variant. Recorded as PARTIAL with evidence_source IN_VITRO because it is an edited-cell phenotype, not a demonstration of the human disease mechanism.
PMID:29263846 SUPPORT Human Clinical
"our observations suggest TTN as a candidate predisposing gene in classic PTEN-wildtype BRRS patients, perhaps suggesting this syndrome join the growing list of Titinopathies"
The authors' own framing as a candidate gene, which is why this is curated as SUSCEPTIBILITY rather than CAUSATIVE.
💊

Medical Actions

7
Lifelong Cancer Surveillance
Action: cancer surveillanceNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is cancer surveillance, annotated with Cancer Screening (NCIT:C15406). NCIT:C15406 is a clinical intervention from the NCI Thesaurus. Ontology label: Cancer Screening NCIT:C15406
The central management intervention. Because PTEN-positive BRRS carries the same cancer burden as Cowden syndrome, surveillance is identical and lifelong: annual thyroid ultrasound and skin examination from the time of diagnosis in childhood; in adults, annual thyroid ultrasound and dermatologic evaluation; from age 30 in women, breast screening with consideration of endometrial assessment from age 35; colonoscopy from age 35 with intervals set by polyp burden; and biennial renal imaging from age 40. Family history of early-onset cancer should pull screening earlier by 5 to 10 years.
Show evidence (6 references)
PMID:10400993 SUPPORT Human Clinical
"Thus, PTEN mutation-positive CS and BRR may be different presentations of a single syndrome and, hence, both should receive equal attention with respect to cancer surveillance."
The primary justification for applying full Cowden-equivalent surveillance to PTEN-positive BRRS.
PMID:20301661 SUPPORT Human Clinical
"Yearly thyroid ultrasound from the time of diagnosis (earliest reported at age 7 years) and skin check with physical examination."
GeneReviews pediatric surveillance recommendation, directly applicable to childhood-diagnosed BRRS.
PMID:20301661 SUPPORT Human Clinical
"Men and women. Colonoscopy beginning at age 35 years with frequency dependent on degree of polyposis identified or family history of early-onset colon cancer (before age 40); biennial (every 2 years) renal imaging (CT or MRI preferred) beginning at age 40 years."
GeneReviews colorectal and renal surveillance schedule.
+ 3 more references
Gastrointestinal Polyp Management
Action: endoscopic polypectomyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is endoscopic polypectomy, annotated with Surgical Procedure (NCIT:C15329). NCIT:C15329 is a clinical intervention from the NCI Thesaurus. Ontology label: Surgical Procedure NCIT:C15329
Symptomatic or large hamartomatous polyps are managed endoscopically with polypectomy, with colonoscopic surveillance intervals determined by polyp burden. Benign gastrointestinal lesions are common enough in PTEN carriers that structured colorectal screening is recommended rather than symptom-driven assessment alone.
Show evidence (1 reference)
PMID:22672595 SUPPORT Human Clinical
"Colorectal screening of patients with germline PTEN mutations is recommended, starting at age 40 years."
Supports structured colorectal screening in PTEN carriers. Note this cohort proposes age 40, whereas GeneReviews recommends starting at 35.
Symptomatic Management of Hamartomatous Lesions
Action: surgical excisionNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is surgical excision, annotated with Surgical Procedure (NCIT:C15329). NCIT:C15329 is a clinical intervention from the NCI Thesaurus. Ontology label: Surgical Procedure NCIT:C15329
Lipomas, vascular lesions, and other benign manifestations are treated the same way as their sporadic counterparts, with excision reserved for lesions causing pain, functional impairment, deformity, or diagnostic uncertainty rather than performed prophylactically.
Show evidence (2 references)
PMID:20301661 SUPPORT Human Clinical
"Treatment for the benign and malignant manifestations of PHTS is the same as for their sporadic counterparts."
GeneReviews establishes the principle of treating manifestations as for sporadic disease.
PMID:20301661 SUPPORT Human Clinical
"cutaneous lesions should be excised only if malignancy is suspected or symptoms (e.g., pain, deformity, increased scarring) are significant."
GeneReviews supports restricting excision to symptomatic or suspicious lesions.
Developmental and Behavioral Support
Action: rehabilitationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is rehabilitation (NCIT:C15315). NCIT:C15315 is a clinical intervention from the NCI Thesaurus. Ontology label: Rehabilitation NCIT:C15315
Because developmental delay, intellectual disability, and autism spectrum characteristics are core to the BRRS presentation, early developmental assessment and intervention (speech, motor, and educational support) is a management priority independent of the cancer-surveillance agenda.
Show evidence (1 reference)
PMID:28526761 SUPPORT Human Clinical
"Early paediatric diagnosis is important for institution of medical and developmental surveillance as well as for testing other at- risk family members."
Supports developmental surveillance and support as an explicit goal of early pediatric diagnosis.
mTOR Inhibitor Therapy
Action: mTOR inhibitor pharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is mTOR inhibitor pharmacotherapy, annotated with Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. Ontology label: Pharmacotherapy NCIT:C15986
Agent: everolimus CHEBI:68478 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses everolimus (CHEBI:68478). CHEBI:68478 is a therapeutic agent from Chemical Entities of Biological Interest.
Everolimus targets the mTOR overactivity that follows PTEN loss, giving a direct mechanistic rationale. A 6-month phase II randomized placebo-controlled trial in 46 individuals with PHTS aged 5 to 45 found the drug tolerable but did not meet its primary neurocognitive endpoint, with gastrointestinal adverse events more common on treatment. mTOR inhibition therefore remains investigational for the neurodevelopmental features of BRRS and is not routine care.
Mechanism Target:
INHIBITS PIP3 Accumulation and PI3K-AKT-mTOR Hyperactivation — Everolimus inhibits mTORC1 downstream of the PIP3/AKT node, partially offsetting the signaling excess caused by PTEN loss.
Show evidence (3 references)
PMID:35594551 SUPPORT Human Clinical
"PTEN hamartoma tumor syndrome (PHTS) is a complex neurodevelopmental disorder characterized by mechanistic target of rapamycin (mTOR) overactivity."
Establishes the mechanistic rationale for mTOR inhibition in PHTS.
PMID:35594551 REFUTE Human Clinical
"Changes in the primary endpoint between groups from baseline to Month 6 were not apparent"
Recorded as REFUTE for the claim of neurocognitive efficacy. The randomized trial's primary endpoint was null, which is why this treatment is curated as investigational rather than established.
PMID:35594551 SUPPORT Human Clinical
"Gastrointestinal adverse events were more common in the everolimus group"
Documents the principal treatment-emergent toxicity signal in the trial.
Sirolimus for Vascular Anomalies
Action: mTOR inhibitor pharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is mTOR inhibitor pharmacotherapy, annotated with Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. Ontology label: Pharmacotherapy NCIT:C15986
Agent: sirolimus CHEBI:9168 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses sirolimus (CHEBI:9168). CHEBI:9168 is a therapeutic agent from Chemical Entities of Biological Interest.
Sirolimus (rapamycin) is the lesion-directed mTOR-inhibitor use in BRRS, distinct from the neurocognitive indication that the everolimus trial tested and missed. It is used off-label for symptomatic vascular anomalies when other treatments have failed, and the BRRS-specific published experience is a single pediatric case in the 2024 systematic review. Evidence is therefore anecdotal, and this is curated as an off-label option under investigation rather than standard care.
Mechanism Target:
INHIBITS PTEN Hamartoma of Soft Tissue Formation — Sirolimus acts on the lesion itself: mTORC1 inhibition shrinks the intramuscular fat-and-vessel overgrowth, which is why the reported benefit is lesion size and symptom relief rather than a systemic disease-modifying effect.
INHIBITS PIP3 Accumulation and PI3K-AKT-mTOR Hyperactivation — The upstream pharmacological rationale: sirolimus inhibits mTORC1 downstream of the PIP3/AKT node.
Show evidence (3 references)
PMID:39256443 SUPPORT Human Clinical
"mTOR inhibitors have been investigated in patients with vascular anomalies when previous treatments were ineffective"
Establishes the lesion-directed indication. PARTIAL because it describes an investigational, salvage-setting use rather than established efficacy.
PMID:39256443 SUPPORT Human Clinical
"only one study reported the use of rapamycin"
Quantifies how thin the BRRS-specific evidence is: a single report among 33 reviewed articles, which is why this is curated as anecdotal rather than standard care.
PMID:39256443 SUPPORT Human Clinical
"There is no established standard treatment for PHTS patients"
Confirms the absence of an established standard therapy in PHTS, the framing under which any mTOR-inhibitor use in BRRS should be read.
Genetic Counseling and Cascade Testing
Action: Genetic CounselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Genetic Counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. NCIT:C15240
Genetic counseling covers the autosomal dominant 50% transmission risk, the variable expressivity that lets one PTEN variant produce BRRS in one relative and Cowden syndrome in another, and the value of predictive testing in at-risk relatives so that carriers can enter surveillance.
Show evidence (2 references)
PMID:20301661 SUPPORT Human Clinical
"When a PTEN pathogenic variant has been identified in a proband, molecular genetic testing of asymptomatic at-risk relatives can identify those who have the family-specific pathogenic variant and warrant ongoing surveillance."
GeneReviews supports cascade testing of at-risk relatives to direct surveillance.
PMID:10353779 SUPPORT Human Clinical
"To our knowledge, this is the first report that shows the presence of separate subjects with CS and with BZS in a single family associated with a single germline PTEN mutation."
Supports counseling about intrafamilial variable expressivity: the same variant can produce either BRRS or Cowden syndrome in different relatives.
🔬

Diagnosis

2
PTEN Molecular Genetic Testing
Definitive diagnosis rests on identifying a heterozygous germline PTEN pathogenic variant. Because a substantial minority of clinically diagnosed BRRS cases have no detectable PTEN variant, a negative result does not overturn a clinical diagnosis, and such individuals are still generally managed with surveillance. Testing is tiered, and sequencing alone is not sufficient. Coding-region sequencing is the first step, but contiguous-gene and whole/multi-exon deletions at 10q23 are invisible to it and require deletion/duplication analysis (MLPA) or chromosomal microarray — the 10q23 PTEN-plus-BMPR1A deletion subtype curated in this entry is found only that way. Assay design must also contend with the processed pseudogene PTENP1 on chromosome 9, which cross-amplifies with PTEN.
Show evidence (3 references)
PMID:18510548 SUPPORT Human Clinical
"The sizes of the deletions were analyzed using single nucleotide polymorphism array analysis."
Supports the need for array-based rather than sequencing-only testing to detect the 10q23 contiguous deletions described in this section.
PMID:21177507 SUPPORT Human Clinical
"Other mechanisms of loss of function such as hypermethylation, which should result in underexpression of PTEN or of KILLIN, a novel tumor suppressor transcribed in the opposite direction, may account for the remainder of Cowden syndrome and Cowden-like syndro"
Supports germline promoter hypermethylation as a testable non-sequence mechanism in mutation-negative cases, which is why the workup does not stop at sequencing.
PMID:20301661 SUPPORT Human Clinical
"The diagnosis of PHTS is established in a proband by identification of a heterozygous germline PTEN pathogenic variant on molecular genetic testing."
GeneReviews states the molecular basis of establishing the PHTS diagnosis.
Clinical Recognition in Childhood
BRRS is recognized clinically in a child with macrocephaly plus some combination of hamartomatous gastrointestinal polyposis, multiple lipomas, and pigmented macules of the glans penis, often alongside developmental delay or autism spectrum features. Because dermatologic, gastrointestinal, and thyroid findings are age-dependent, their absence at first assessment does not exclude the diagnosis.
Show evidence (2 references)
PMID:37900693 SUPPORT Human Clinical
"This syndrome is occasionally diagnosed in childhood due to the occurrence of multiple gastrointestinal polyps, autism spectrum disorders, and intellectual disability."
Guideline statement describing the childhood route to diagnosis that characterizes the BRRS presentation.
PMID:28526761 SUPPORT Human Clinical
"Dermatological, GI and thyroid abnormalities are age dependent and may not be present at the time of diagnosis, requiring regular monitoring and medical surveillance."
Supports the caution that age-dependent features may be absent at initial pediatric assessment.
📊

Prevalence

1
Worldwide
Unknown Unknown
No reliable population-level prevalence estimate exists for BRRS specifically. Published PHTS epidemiology is dominated by adult, cancer-ascertained Cowden syndrome cohorts, and the childhood-onset BRRS presentation is systematically under-represented, so no numeric rate is asserted here.
Show evidence (1 reference)
PMID:33140411 SUPPORT Human Clinical
"Although these estimates provide guidance for clinical care, discrepancies between studies, sample sizes, retrospective designs, strongly ascertained cases, and lack of pediatric research emphasizes that data should be interpreted with great caution."
Supports the stated epidemiological uncertainty: this systematic review of PHTS cohorts explicitly flags ascertainment bias and absent pediatric data, which is why no numeric BRRS prevalence is recorded.
🔀

Differential Diagnoses

2

Conditions with similar clinical presentations that must be differentiated from Bannayan-Riley-Ruvalcaba Syndrome:

Cowden Syndrome
Overlapping Features The adult-presenting allelic PHTS phenotype. Distinguished by trichilemmomas and mucocutaneous papillomatous papules with presentation in the late 20s, rather than the congenital macrocephaly, polyposis, lipoma, and genital lentiginosis pattern of BRRS. The distinction is clinical and developmental, not molecular: both arise from germline PTEN variants and both require the same cancer surveillance.
Show evidence (1 reference)
PMID:10400993 SUPPORT Human Clinical
"Pigmented macules of the glans penis, delayed motor development and neonatal or infant onset are noted only in BRR."
Gives the specific features that separate BRRS from Cowden syndrome clinically.
Juvenile Polyposis Syndrome
Overlapping Features Shares hamartomatous gastrointestinal polyposis with BRRS and was historically considered a possible variant of it, but is caused by SMAD4 or BMPR1A variants and lacks macrocephaly, lipomas, and genital lentiginosis.
Show evidence (1 reference)
PMID:9352843 SUPPORT Human Clinical
"It has been suggested that Bannayan-Riley-Ruvalcaba syndrome may be a variant of juvenile polyposis coli because of the shared features of intestinal juvenile polyps."
Documents the historical diagnostic confusion between BRRS and juvenile polyposis based on shared polyp histology.
{ }

Source YAML

click to show 
name: Bannayan-Riley-Ruvalcaba Syndrome
creation_date: "2026-08-03T00:00:00Z"
description: >-
  Bannayan-Riley-Ruvalcaba syndrome (BRRS) is the congenital, pediatric-onset
  presentation within the PTEN hamartoma tumor syndrome (PHTS) spectrum, caused by
  heterozygous germline loss-of-function variants in the tumor suppressor PTEN.
  Loss of PTEN lipid-phosphatase activity removes the brake on
  phosphatidylinositol-3,4,5-trisphosphate signaling, driving constitutive
  PI3K/AKT/mTOR activation and disorganized overgrowth of native tissue.
  The clinical hallmarks are macrocephaly, hamartomatous intestinal polyposis,
  multiple lipomas, and pigmented macules of the glans penis, usually accompanied by
  developmental delay, hypotonia, and autism spectrum features. Because BRRS and
  Cowden syndrome are allelic and can co-occur within a single family carrying one
  PTEN variant, PTEN-positive BRRS is now managed with the same lifelong cancer
  surveillance as Cowden syndrome rather than as a benign childhood overgrowth
  syndrome.
category: Mendelian
disease_term:
  preferred_term: Bannayan-Riley-Ruvalcaba syndrome
  term:
    id: MONDO:0007924
    label: Bannayan-Riley-Ruvalcaba syndrome
synonyms:
- BRRS
- Bannayan-Zonana syndrome
- Bannayan syndrome
- Riley-Smith syndrome
- Ruvalcaba-Myhre-Smith syndrome
- Macrocephaly with multiple lipomas and hemangiomas
parents:
- Autosomal dominant hereditary syndrome
- Hereditary cancer syndrome
- PTEN hamartoma tumor syndrome
prevalence:
- population: Worldwide
  measure_type: UNKNOWN
  prevalence_class: UNKNOWN
  notes: >-
    No reliable population-level prevalence estimate exists for BRRS specifically.
    Published PHTS epidemiology is dominated by adult, cancer-ascertained Cowden
    syndrome cohorts, and the childhood-onset BRRS presentation is systematically
    under-represented, so no numeric rate is asserted here.
  evidence:
  - reference: PMID:33140411
    reference_title: A review on age-related cancer risks in PTEN hamartoma tumor syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Although these estimates provide guidance for clinical care, discrepancies between studies, sample sizes, retrospective designs, strongly ascertained cases, and lack of pediatric research emphasizes that data should be interpreted with great caution."
    explanation: >-
      Supports the stated epidemiological uncertainty: this systematic review of PHTS
      cohorts explicitly flags ascertainment bias and absent pediatric data, which is why
      no numeric BRRS prevalence is recorded.
inheritance:
- name: Autosomal dominant inheritance
  description: >-
    BRRS is inherited in an autosomal dominant manner as part of PHTS. Each child of an
    affected individual has a 50% chance of inheriting the pathogenic PTEN variant.
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  evidence:
  - reference: PMID:20301661
    reference_title: PTEN Hamartoma Tumor Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PHTS is inherited in an autosomal dominant manner."
    explanation: GeneReviews states the autosomal dominant inheritance of PHTS, which subsumes BRRS.
  - reference: PMID:20301661
    reference_title: PTEN Hamartoma Tumor Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Each child of an affected individual has a 50% chance of inheriting the pathogenic variant and developing PHTS."
    explanation: GeneReviews gives the 50% transmission risk implied by autosomal dominant inheritance.
  - reference: PMID:39256443
    reference_title: A systematic review of Bannayan - Riley - Ruvalcaba syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PTEN pathogenic variants in BRRS cases usually demonstrate autosomal dominant inheritance; nevertheless, it is estimated that up to 48% of pathogenic variants can be de novo"
    explanation: >-
      Confirms autosomal dominant inheritance in BRRS specifically and adds the clinically
      important point that up to 48% of variants arise de novo, so an unremarkable family
      history does not argue against the diagnosis.
has_subtypes:
- name: 10q23 deletion
  display_name: 10q23 contiguous-gene deletion (PTEN + BMPR1A)
  description: >-
    A contiguous-gene deletion at 10q23 removing both PTEN and BMPR1A, combining BRRS
    features with juvenile polyposis. It was originally described in infantile juvenile
    polyposis with a severe course, and was hypothesized to reflect a synergistic effect of
    losing both tumor suppressors. Subsequent series found the phenotype is variable rather
    than uniformly severe, and severity does not track deletion size. Recognizing this
    subtype matters practically: it is missed by sequencing alone and requires
    deletion/duplication testing or chromosomal microarray, and it explains the otherwise
    puzzling overlap with juvenile polyposis in the differential.
  evidence:
  - reference: PMID:18510548
    reference_title: Variable phenotypes associated with 10q23 microdeletions involving the PTEN and BMPR1A genes.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Recently, 10q23 microdeletions involving the PTEN and BMPR1A genes were found in four patients with infantile juvenile polyposis. It was hypothesized that a combined and synergistic effect of the deletion of both genes would explain the condition."
    explanation: Establishes the contiguous-deletion entity and the original two-gene synergy hypothesis.
  - reference: PMID:18510548
    reference_title: Variable phenotypes associated with 10q23 microdeletions involving the PTEN and BMPR1A genes.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All patients had macrocephaly, dysmorphic features, retardation and congenital abnormalities."
    explanation: >-
      Documents the BRRS-like core (macrocephaly, developmental delay) in deletion carriers.
      PARTIAL because this is a four-patient series.
  - reference: PMID:18510548
    reference_title: Variable phenotypes associated with 10q23 microdeletions involving the PTEN and BMPR1A genes.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "No clear correlation was found between ages at onset or severity of gastrointestinal symptoms and the sizes of the deletions."
    explanation: >-
      Recorded as REFUTE against the simple dose/size-severity model: deletion size does not
      predict severity, which is why this subtype is described as variable rather than
      uniformly severe.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_pi3k_akt_mtor
  hypothesis_label: Canonical PI3K-AKT-mTOR dose-sensitive overgrowth
  status: CANONICAL
  description: >-
    The default model: PTEN haploinsufficiency raises PIP3, activating PI3K/AKT/mTORC1 and
    driving growth, survival, and proliferation across lineages. Every BRRS manifestation
    in this entry is modeled as downstream of this chain unless otherwise grouped.
  evidence:
  - reference: PMID:35594551
    reference_title: A randomized controlled trial of everolimus for neurocognitive symptoms in PTEN hamartoma tumor syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PTEN hamartoma tumor syndrome (PHTS) is a complex neurodevelopmental disorder characterized by mechanistic target of rapamycin (mTOR) overactivity."
    explanation: States mTOR overactivity as the accepted molecular characterization of PHTS.
- hypothesis_group_id: pten_nuclear_localization_split
  hypothesis_label: Subcellular localization determines the autism-versus-cancer divergence
  status: EMERGING
  description: >-
    Proposes that WHERE PTEN is, not only how much of it there is, decides which arm of the
    phenotype a carrier expresses. PTEN shuttles to the nucleus, and variants that deplete
    nuclear PTEN while sparing total protein are proposed to segregate with the
    ASD/macrocephaly presentation rather than the cancer presentation. If correct, this
    would explain why some PTEN carriers present as neurodevelopmental BRRS and others as
    adult-onset Cowden cancer risk despite comparable PTEN dosage, and it predicts that
    localization, not dosage, should stratify surveillance. Evidence is currently confined
    to the cytoplasmic-predominant Pten mouse; no human genotype-localization-phenotype
    series exists, which is why this is EMERGING rather than ALTERNATIVE.
  evidence:
  - reference: PMID:32055008
    reference_title: Cytoplasmic-predominant Pten increases microglial activation and synaptic pruning in a murine model with autism-like phenotype.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "To explore the importance of nuclear PTEN in the development of ASD and macrocephaly, we previously generated a mouse model with predominantly cytoplasmic localization of Pten"
    explanation: >-
      States the localization hypothesis and the model built to test it. PARTIAL and
      MODEL_ORGANISM because the human translational claim is untested.
  - reference: PMID:24470394
    reference_title: Germline disruption of Pten localization causes enhanced sex-dependent social motivation and increased glial production.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "PTEN Hamartoma Tumor Syndrome (PHTS) is an autosomal-dominant genetic condition underlying a subset of autism spectrum disorder (ASD) with macrocephaly."
    explanation: >-
      Companion model study establishing that disrupting Pten localization alone produces
      behavioral and glial phenotypes. PARTIAL/MODEL_ORGANISM for the same reason.
- hypothesis_group_id: pi3k_independent_overgrowth
  hypothesis_label: PI3K-independent overgrowth via focal adhesion signaling
  status: EMERGING
  description: >-
    Proposes a route to the same overgrowth output that does not pass through PIP3/AKT. In
    PTEN-wildtype classic BRRS, germline TTN variants are enriched, and an edited I-band
    variant produced loss of contact inhibition associated with focal adhesion kinase
    changes rather than increased AKT signaling. If real, this would mean mutation-negative
    BRRS is not simply undetected PTEN disease and may not respond to mTOR-directed
    therapy the way PTEN-positive disease is presumed to.
  evidence:
  - reference: PMID:29263846
    reference_title: Germline TTN variants are enriched in PTEN-wildtype Bannayan-Riley-Ruvalcaba syndrome.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "suggested lack of contact inhibition in mutant cells"
    explanation: >-
      The functional observation underpinning this hypothesis. PARTIAL/IN_VITRO: an edited
      cell line, not a demonstration in human tissue.
pathophysiology:
- name: Germline PTEN Loss of Function
  biological_scale: MOLECULAR
  description: >-
    A heterozygous germline loss-of-function variant in PTEN at chromosome 10q23 is the
    initiating lesion. PTEN encodes a dual-specificity phosphatase whose principal
    physiological substrate is the membrane phospholipid
    phosphatidylinositol-3,4,5-trisphosphate. Germline PTEN variants are identified in
    roughly 60% of clinically diagnosed BRRS cases, so a negative test does not exclude
    the clinical diagnosis.
  genes:
  - preferred_term: PTEN
    term:
      id: hgnc:9588
      label: PTEN
  molecular_functions:
  - preferred_term: PIP3 3-phosphatase activity
    term:
      id: GO:0016314
      label: phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase activity
    modifier: DECREASED
  evidence:
  - reference: PMID:10400993
    reference_title: PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PTEN maps to 10q23 and encodes a dual specificity phosphatase, a substrate of which is phosphatidylinositol 3,4,5-triphosphate, a phospholipid in the phosphatidylinositol 3-kinase pathway."
    explanation: >-
      Establishes the gene location and the molecular identity of PTEN as the phosphatase
      acting on PIP3, the substrate whose dephosphorylation is lost in BRRS.
  - reference: PMID:10400993
    reference_title: PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mutations were identified in 26 of 43 (60%) BRR cases."
    explanation: >-
      Quantifies the germline PTEN detection rate in a dedicated BRRS cohort, supporting
      both the causal gene assignment and the incomplete molecular yield.
  - reference: PMID:9352843
    reference_title: Localization of the Bannayan-Riley-Ruvalcaba syndrome gene to chromosome 10q23.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The three hamartomatous polyposis syndromes, Bannayan-Riley-Ruvalcaba syndrome, juvenile polyposis coli, and Cowden disease, may share the same genetic defect because of their common map localization to chromosome 10q23."
    explanation: >-
      The original positional mapping study that localized the BRRS locus to 10q23, the
      interval subsequently shown to contain PTEN.
  downstream:
  - target: PIP3 Accumulation and PI3K-AKT-mTOR Hyperactivation
    causal_link_type: DIRECT
    description: >-
      Loss of PTEN lipid-phosphatase activity leaves PIP3 undephosphorylated, directly
      releasing downstream PI3K/AKT/mTOR signaling from negative regulation.
    evidence:
    - reference: PMID:10400993
      reference_title: PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "PTEN maps to 10q23 and encodes a dual specificity phosphatase, a substrate of which is phosphatidylinositol 3,4,5-triphosphate, a phospholipid in the phosphatidylinositol 3-kinase pathway."
      explanation: >-
        Supports the edge specifically: PTEN's substrate is PIP3 within the PI3K pathway, so
        losing PTEN function is what releases that pathway.
- name: PIP3 Accumulation and PI3K-AKT-mTOR Hyperactivation
  biological_scale: MOLECULAR
  description: >-
    With PTEN-mediated dephosphorylation lost, PIP3 accumulates at the plasma membrane
    and recruits AKT, producing constitutive PI3K/AKT/mTOR signaling. The resulting
    mTOR overactivity increases cell growth, protein synthesis, and survival signaling
    across many lineages and is the shared molecular engine of every downstream BRRS
    manifestation. This node is also the pharmacological rationale for mTOR-inhibitor
    trials in PHTS.
  biological_processes:
  - preferred_term: PI3K/AKT signaling
    term:
      id: GO:0043491
      label: phosphatidylinositol 3-kinase/protein kinase B signal transduction
    modifier: INCREASED
  - preferred_term: mTOR signaling
    term:
      id: GO:0031929
      label: TOR signaling
    modifier: INCREASED
  evidence:
  - reference: PMID:35594551
    reference_title: A randomized controlled trial of everolimus for neurocognitive symptoms in PTEN hamartoma tumor syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PTEN hamartoma tumor syndrome (PHTS) is a complex neurodevelopmental disorder characterized by mechanistic target of rapamycin (mTOR) overactivity."
    explanation: >-
      States mTOR overactivity as the defining molecular consequence of germline PTEN loss
      in PHTS, the mechanism this node models.
  downstream:
  - target: Hamartomatous Tissue Overgrowth
    causal_link_type: DIRECT
    description: >-
      Constitutive growth and survival signaling drives disorganized proliferation of
      native tissue elements, producing hamartomas. This edge carries two competing
      explanations: the canonical PIP3/AKT/mTOR route, and an emerging PI3K-independent
      route via focal adhesion signaling proposed for PTEN-wildtype BRRS.
    hypothesis_groups:
    - canonical_pi3k_akt_mtor
    - pi3k_independent_overgrowth
    evidence:
    - reference: PMID:39256443
      reference_title: A systematic review of Bannayan - Riley - Ruvalcaba syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Bannayan-Riley-Ruvalcaba syndrome (BRRS) is a rare overgrowth condition caused by a pathogenic variant in the phosphatase and tensin homolog (PTEN) gene and belongs to a group of disorders called PTEN hamartoma tumor syndrome (PHTS)."
      explanation: >-
        Supports the edge by identifying BRRS as an overgrowth/hamartoma condition whose
        cause is the PTEN lesion feeding this signaling node.
  - target: Neural Progenitor Overgrowth and Brain Enlargement
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      mTORC1-driven increases in cell size and progenitor output enlarge the brain.
    hypothesis_groups:
    - canonical_pi3k_akt_mtor
  - target: Synaptic and Circuit Development Dysregulation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      The same signaling excess perturbs synaptic and circuit development, a functional
      output separable from brain size.
    hypothesis_groups:
    - canonical_pi3k_akt_mtor
    - pten_nuclear_localization_split
    evidence:
    - reference: PMID:35594551
      reference_title: A randomized controlled trial of everolimus for neurocognitive symptoms in PTEN hamartoma tumor syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "PTEN hamartoma tumor syndrome (PHTS) is a complex neurodevelopmental disorder characterized by mechanistic target of rapamycin (mTOR) overactivity."
      explanation: >-
        Supports the edge by tying the neurodevelopmental phenotype of PHTS directly to mTOR
        overactivity, the upstream node here.
  - target: Lifelong Multiorgan Cancer Predisposition
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Sustained proliferative and antiapoptotic signaling in a germline-haploinsufficient
      background permits second-hit-dependent malignant transformation over decades.
    hypothesis_groups:
    - canonical_pi3k_akt_mtor
    - pten_nuclear_localization_split
    evidence:
    - reference: PMID:33140411
      reference_title: A review on age-related cancer risks in PTEN hamartoma tumor syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Patients with PTEN hamartoma tumor syndrome (PHTS, comprising Cowden, Bannayan-Riley-Ruvalcaba, and Proteus-like syndromes) are at increased risk of developing cancer due to pathogenic PTEN germline variants."
      explanation: >-
        Supports the edge from germline-PTEN-driven signaling loss to multiorgan cancer risk,
        with BRRS named within the affected group.
  - target: Penile freckling
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Genital lentiginosis is a highly specific BRRS sign attributed to PTEN-driven
      melanocytic dysregulation, but the intermediate steps linking PI3K/AKT/mTOR
      activation to focal glans pigmentation are not established.
    evidence:
    - reference: PMID:10400993
      reference_title: PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Pigmented macules of the glans penis, delayed motor development and neonatal or infant onset are noted only in BRR."
      explanation: >-
        Establishes that the sign occurs in BRRS specifically. Recorded as PARTIAL because it
        supports the association only, not the mechanistic route from PTEN loss to focal
        pigmentation, which is why the edge is INDIRECT_UNKNOWN_INTERMEDIATES.
- name: Hamartomatous Tissue Overgrowth
  biological_scale: TISSUE
  description: >-
    Unrestrained growth signaling produces hamartomas: benign, disorganized overgrowths
    composed of cell types native to the tissue of origin. In BRRS this is expressed
    predominantly as hamartomatous polyps distributed throughout the gastrointestinal
    tract, subcutaneous and visceral lipomas, and vascular lesions, and it is the
    substrate for the syndrome's structural burden in childhood.
  cell_types:
  - preferred_term: adipocyte
    term:
      id: CL:0000136
      label: adipocyte
  - preferred_term: intestinal epithelial cell
    term:
      id: CL:0002563
      label: intestinal epithelial cell
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  biological_processes:
  - preferred_term: cell proliferation
    term:
      id: GO:0008283
      label: cell population proliferation
    modifier: INCREASED
  evidence:
  - reference: PMID:9352843
    reference_title: Localization of the Bannayan-Riley-Ruvalcaba syndrome gene to chromosome 10q23.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bannayan-Riley-Ruvalcaba syndrome is a congenital syndrome with characteristic features of macrocephaly, cognitive and motor dysfunction, subcutaneous and visceral lipomas and hemangiomas, and intestinal juvenile polyposis."
    explanation: >-
      Enumerates the hamartomatous tissue lesions (lipomas, hemangiomas, intestinal
      polyposis) that constitute this overgrowth node in BRRS.
  - reference: PMID:20301661
    reference_title: PTEN Hamartoma Tumor Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "BRRS is a congenital disorder characterized by macrocephaly, intestinal hamartomatous polyposis, lipomas, and pigmented macules of the glans penis."
    explanation: >-
      The GeneReviews definition of BRRS, confirming hamartomatous polyposis and lipomas as
      defining tissue-level manifestations.
  downstream:
  - target: Hamartomatous polyposis
    causal_link_type: DIRECT
  - target: Lipoma
    causal_link_type: DIRECT
  - target: Hemangioma
    causal_link_type: DIRECT
  - target: PTEN Hamartoma of Soft Tissue Formation
    causal_link_type: DIRECT
    description: >-
      The overgrowth program produces the distinctive intramuscular mesenchymal lesion of
      PHTS, combining ectopic fat with malformed fast-flow vessels.
- name: PTEN Hamartoma of Soft Tissue Formation
  biological_scale: TISSUE
  description: >-
    The distal, lesion-level node of the overgrowth arm. PTEN hamartoma of soft tissue
    (PHOST) is a distinctive, predominantly intramuscular lesion of PHTS: a disorganized
    overgrowth of mesenchymal elements combining ectopic adipose tissue, fibrous tissue,
    and malformed fast-flow vascular channels. It is radiologically mistaken for a simple
    arteriovenous malformation but is histologically distinct, and it is the lesion that
    drives pain, swelling, and functional loss in BRRS. It is the specific target of
    sirolimus therapy in this entry.
  cell_types:
  - preferred_term: adipocyte
    term:
      id: CL:0000136
      label: adipocyte
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  - preferred_term: fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  evidence:
  - reference: PMID:22446940
    reference_title: "PTEN hamartoma of soft tissue: a distinctive lesion in PTEN syndromes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We designate this disorganized overgrowth of essentially mesenchymal elements as PTEN hamartoma of soft tissue."
    explanation: >-
      The defining pathological description of PHOST, establishing this node as a
      distinct lesion entity rather than a generic vascular malformation.
  - reference: PMID:22446940
    reference_title: "PTEN hamartoma of soft tissue: a distinctive lesion in PTEN syndromes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lesions manifested by 15 years of age, normally with pain and swelling, and were most often located in the lower extremity."
    explanation: >-
      Establishes the pediatric onset and the clinical burden (pain, swelling) that makes
      this node the target of lesion-directed therapy in BRRS.
  - reference: PMID:17526801
    reference_title: "The spectrum of vascular anomalies in patients with PTEN mutations: implications for diagnosis and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Vascular anomalies were found in 14/26 (54%) of patients: 8/14 (57%) had multiple lesions and 11/13 (85%) who had cross-sectional imaging had intramuscular vascular lesions."
    explanation: >-
      Quantifies frequency and the characteristic intramuscular location in a PTEN-mutation
      cohort.
  - reference: PMID:17526801
    reference_title: "The spectrum of vascular anomalies in patients with PTEN mutations: implications for diagnosis and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Vascular anomalies in patients with a PTEN mutation are typically multifocal intramuscular combinations of fast-flow channels and ectopic fat."
    explanation: >-
      The combined vascular-plus-adipose composition that distinguishes PHOST from an
      ordinary arteriovenous malformation, and the basis for the cell types on this node.
  downstream:
  - target: Arteriovenous malformation
    causal_link_type: DIRECT
    description: >-
      PHOST is the lesion most often reported clinically as an arteriovenous malformation
      in BRRS, which is the phenotype term this entry binds.
- name: Neural Progenitor Overgrowth and Brain Enlargement
  biological_scale: TISSUE
  description: >-
    The structural arm of PTEN loss in the nervous system. PTEN is a strong negative
    regulator of growth in neural lineages, so mTORC1-driven increases in cell size and
    progenitor output enlarge the brain. Clinically this is marked macrocephaly, typically
    evident from infancy and non-progressive after early childhood, and it is
    megalencephaly rather than hydrocephalus.
  cell_types:
  - preferred_term: neural progenitor cell
    term:
      id: CL:0011020
      label: neural progenitor cell
  biological_processes:
  - preferred_term: neurogenesis
    term:
      id: GO:0022008
      label: neurogenesis
    modifier: INCREASED
  evidence:
  - reference: PMID:32055008
    reference_title: Cytoplasmic-predominant Pten increases microglial activation and synaptic pruning in a murine model with autism-like phenotype.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "predominant Pten localization results in a phenotype of extreme macrocephaly and autistic-like traits"
    explanation: >-
      Mouse model showing that perturbing Pten produces brain overgrowth. Typed
      MODEL_ORGANISM; the human macrocephaly phenotype itself is separately supported by
      human clinical evidence on the Macrocephaly phenotype entry.
  - reference: PMID:31609537
    reference_title: "PTEN Hamartoma tumor syndrome in childhood: A review of the clinical literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PTEN hamartoma tumor syndrome (PHTS) is a highly variable autosomal dominant condition associated with intellectual disability, overgrowth, and tumor predisposition phenotypes, which often overlap."
    explanation: Human review linking PHTS to an overgrowth phenotype, the output of this node.
  downstream:
  - target: Macrocephaly
    causal_link_type: DIRECT
    hypothesis_groups:
    - pten_nuclear_localization_split
- name: Synaptic and Circuit Development Dysregulation
  biological_scale: CELLULAR
  description: >-
    The functional arm of PTEN loss in the nervous system, distinct from and not reducible
    to brain size. Disrupted synaptic and circuit development manifests as hypotonia,
    delayed motor milestones, global developmental delay, intellectual disability, and
    autism spectrum characteristics. Neonatal or infantile onset and delayed motor
    development are among the features that historically distinguished BRRS from
    adult-presenting Cowden syndrome. Candidate cellular intermediates include microglial
    activation with excessive synaptic pruning, demonstrated in the cytoplasmic-predominant
    Pten mouse but not yet confirmed in human tissue.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: neuron differentiation
    term:
      id: GO:0030182
      label: neuron differentiation
    modifier: ABNORMAL
  evidence:
  - reference: PMID:10400993
    reference_title: PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pigmented macules of the glans penis, delayed motor development and neonatal or infant onset are noted only in BRR."
    explanation: >-
      Identifies delayed motor development and congenital/infantile onset as BRRS-restricted
      features, supporting this functional arm and its early timing.
  - reference: PMID:34983360
    reference_title: "Behavioural and psychological features of PTEN mutations: a systematic review of the literature and meta-analysis of the prevalence of autism spectrum disorder characteristics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Intellectual disability and developmental delay (global, motor and speech and language) were also reported frequently."
    explanation: >-
      Human systematic review establishing the functional neurodevelopmental outputs modeled
      by this node, independent of head size.
  - reference: PMID:32055008
    reference_title: Cytoplasmic-predominant Pten increases microglial activation and synaptic pruning in a murine model with autism-like phenotype.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We found increased Iba1 and C1q expression with enhanced phagocytic capacity in Ptenm3m4/m3m4 microglia, indicating microglial activation."
    explanation: >-
      Proposes microglial activation and excessive synaptic pruning as the cellular
      intermediate. PARTIAL and MODEL_ORGANISM because this is a mouse result not confirmed
      in human tissue.
  downstream:
  - target: Global developmental delay
    causal_link_type: DIRECT
  - target: Autism
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Autism spectrum characteristics are consistently over-represented in PTEN carriers,
      but the synaptic intermediates linking mTOR overactivity to the behavioral phenotype
      remain incompletely defined.
    hypothesis_groups:
    - pten_nuclear_localization_split
  - target: Intellectual disability
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Hypotonia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Lifelong Multiorgan Cancer Predisposition
  biological_scale: ORGANISM
  description: >-
    Because every cell carries one inactivated PTEN allele, somatic loss of the second
    allele in a susceptible tissue removes tumor-suppressor function entirely and permits
    malignant transformation. The resulting lifetime risks span breast, thyroid,
    endometrial, renal, colorectal, and cutaneous melanocytic malignancy. This node
    carries the central nosological insight of the entry: although malignancy was not
    formally documented in the original BRRS descriptions, PTEN-positive BRRS and Cowden
    syndrome are allelic presentations of one disorder and therefore warrant identical
    cancer surveillance. Cancer risk in BRRS is largely realized in adulthood, so the
    childhood diagnosis obligates lifelong follow-up rather than pediatric oncologic
    treatment.
  cell_types:
  - preferred_term: thyroid follicular cell
    term:
      id: CL:0002258
      label: thyroid follicular cell
  - preferred_term: epithelial cell
    term:
      id: CL:0000066
      label: epithelial cell
  biological_processes:
  - preferred_term: negative regulation of apoptosis
    term:
      id: GO:0043066
      label: negative regulation of apoptotic process
    modifier: INCREASED
  evidence:
  - reference: PMID:10400993
    reference_title: PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thus, PTEN mutation-positive CS and BRR may be different presentations of a single syndrome and, hence, both should receive equal attention with respect to cancer surveillance."
    explanation: >-
      The key conclusion establishing that PTEN-positive BRRS carries the Cowden-equivalent
      cancer burden and must be surveilled accordingly.
  - reference: PMID:10400993
    reference_title: PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    snippet: "CS is characterized by multiple hamartomas and an increased risk of benign and malignant disease of the breast, thyroid and central nervous system, whilst the presence of cancer has not been formally documented in BRR."
    explanation: >-
      Recorded as NO_EVIDENCE because it asserts an absence of evidence rather than
      supporting or refuting the node: malignancy had not been formally established in
      BRRS-ascertained cohorts. It is retained to make
      explicit that the cancer risk attributed to BRRS is inferred from allelism with Cowden
      syndrome rather than from direct BRRS-cohort incidence data.
  - reference: PMID:22252256
    reference_title: Lifetime cancer risks in individuals with germline PTEN mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lifetime risks for a variety of cancers, now extending to colorectal cancer, kidney cancer, and melanoma, are increased in patients with PTEN mutations."
    explanation: >-
      The prospective PHTS cohort establishing that germline PTEN carriers, the molecular
      class to which PTEN-positive BRRS belongs, carry elevated multiorgan cancer risk.
  - reference: PMID:33140411
    reference_title: A review on age-related cancer risks in PTEN hamartoma tumor syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with PTEN hamartoma tumor syndrome (PHTS, comprising Cowden, Bannayan-Riley-Ruvalcaba, and Proteus-like syndromes) are at increased risk of developing cancer due to pathogenic PTEN germline variants."
    explanation: >-
      Explicitly includes BRRS within the PHTS group carrying germline-PTEN-driven cancer
      risk.
  - reference: PMID:39256443
    reference_title: A systematic review of Bannayan - Riley - Ruvalcaba syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with BRRS are considered to share the same lifetime risk of cancer as individuals with Cowden syndrome, however, it has not been confirmed by formal studies"
    explanation: >-
      The most precise available statement of this node's epistemic status, from a
      BRRS-specific systematic review: the Cowden-equivalent cancer risk is the accepted
      clinical assumption but remains formally unconfirmed in BRRS-ascertained cohorts.
      Recorded as PARTIAL for exactly that reason.
  downstream:
  - target: Breast carcinoma
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Thyroid carcinoma
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Endometrial carcinoma
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Renal cell carcinoma
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Colon cancer
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Melanoma
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Hashimoto thyroiditis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Benign thyroid pathology including Hashimoto thyroiditis is over-represented in
      BRRS; the autoimmune intermediates are not modeled here.
    evidence:
    - reference: PMID:10400993
      reference_title: PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Additional features observed in BRR, which may also occur in a minority of CS patients, include Hashimoto's thyroiditis, vascular malformations and mental retardation."
      explanation: >-
        Supports the association of Hashimoto thyroiditis with BRRS. PARTIAL because no
        mechanistic link from PTEN loss to thyroid autoimmunity is established, matching the
        INDIRECT_UNKNOWN_INTERMEDIATES typing.
phenotypes:
- category: Growth
  name: Macrocephaly
  description: >-
    Marked macrocephaly is the most consistent and earliest sign of BRRS, reflecting
    PTEN-driven brain overgrowth rather than hydrocephalus. In a pediatric PHTS series
    the mean head circumference was more than five standard deviations above the mean.
  phenotype_term:
    preferred_term: Macrocephaly
    term:
      id: HP:0000256
      label: Macrocephaly
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:20301661
    reference_title: PTEN Hamartoma Tumor Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "BRRS is a congenital disorder characterized by macrocephaly, intestinal hamartomatous polyposis, lipomas, and pigmented macules of the glans penis."
    explanation: GeneReviews names macrocephaly as a defining feature of BRRS.
  - reference: PMID:28526761
    reference_title: A retrospective chart review of the features of PTEN hamartoma tumour syndrome in children.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Macrocephaly (average head circumference of + 5.7  SD) with developmental delay, ID and/or ASD were the most common presenting signs/symptoms (66 %)."
    explanation: >-
      Supports the disease-phenotype association and quantifies the severity of macrocephaly
      in pediatric PHTS (mean head circumference +5.7 SD). Note this 66% figure is a
      composite presenting-symptom statistic (macrocephaly together with developmental
      delay, ID and/or ASD), not a macrocephaly frequency, so it is not used to set the
      frequency band.
  - reference: PMID:39256443
    reference_title: A systematic review of Bannayan - Riley - Ruvalcaba syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Macrocephaly was described in almost all case reports (32/33)."
    explanation: >-
      The evidence anchoring the VERY_FREQUENT band: macrocephaly reported in 32 of 33
      BRRS case reports (97%), within the 80-100% range.
  - reference: PMID:39256443
    reference_title: A systematic review of Bannayan - Riley - Ruvalcaba syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A total of 83 pediatric patients with BRRS were identified. The most common clinical findings were macrocephaly (77%) and developmental disorders (63%)."
    explanation: >-
      BRRS-specific patient-level frequency (77%), the most common finding in 83 published
      pediatric cases. Documenting a deliberate band choice: taken alone this figure falls
      in FREQUENT (30-79%), and the VERY_FREQUENT band is set instead from the same review's
      report-level tally of 32/33. The patient-level denominator counts cases where the
      feature was explicitly recorded, so it under-counts in case reports focused on other
      findings; the two figures bracket the true frequency at the FREQUENT/VERY_FREQUENT
      boundary.
- category: Gastrointestinal
  name: Hamartomatous polyposis
  description: >-
    Hamartomatous polyps occur throughout the gastrointestinal tract, from stomach to
    colon, and are a defining BRRS feature that frequently prompts the childhood
    diagnosis. Polyps may be numerous and of mixed histologic type, and can present with
    bleeding, anemia, abdominal pain, or intussusception.
  phenotype_term:
    preferred_term: Hamartomatous polyposis
    term:
      id: HP:0004390
      label: Hamartomatous polyposis
  evidence:
  - reference: PMID:20301661
    reference_title: PTEN Hamartoma Tumor Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "BRRS is a congenital disorder characterized by macrocephaly, intestinal hamartomatous polyposis, lipomas, and pigmented macules of the glans penis."
    explanation: GeneReviews names intestinal hamartomatous polyposis as a defining BRRS feature.
  - reference: PMID:34754688
    reference_title: "Diffuse Gastrointestinal Polyposis in Bannayan-Riley-Ruvalcaba Syndrome: A Rare Phenotype Among Phosphatase and Tensin Homolog Hamartoma Tumor Syndromes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The esophagogastroduodenoscopy (EGD) and colonoscopy revealed an erosive gastric mucosa as well as numerous polyps throughout the gastrointestinal tract."
    explanation: >-
      A BRRS case report documenting polyp distribution across both upper and lower
      gastrointestinal tract, supporting the diffuse rather than colon-restricted pattern.
  - reference: PMID:22672595
    reference_title: Is colorectal surveillance indicated in patients with PTEN mutations?
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The cumulative risk of developing benign gastrointestinal polyps was 70% at age 60."
    explanation: >-
      Multinational PTEN-carrier cohort quantifying the cumulative burden of benign
      gastrointestinal polyps.
- category: Dermatologic
  name: Lipoma
  description: >-
    Multiple subcutaneous and visceral lipomas are a hallmark of BRRS and, within BRRS
    cohorts, their presence is statistically associated with carrying an identifiable
    PTEN variant. Lipomas may be numerous, can involve deep or intramuscular sites, and
    are a common source of pain or functional impairment.
  phenotype_term:
    preferred_term: Lipoma
    term:
      id: HP:0012032
      label: Lipoma
  evidence:
  - reference: PMID:10400993
    reference_title: PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The partial clinical overlap in these two syndromes is exemplified by the hallmark features of BRR: macrocephaly and multiple lipomas, the latter of which occur in a minority of individuals with CS."
    explanation: >-
      Identifies multiple lipomas as a hallmark BRRS feature that discriminates it from
      Cowden syndrome, where lipomas are a minority finding.
  - reference: PMID:10400993
    reference_title: PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Additionally, the presence of lipomas was correlated with the presence of PTEN mutation in BRR patients"
    explanation: >-
      Documents the genotype-phenotype correlation between lipomas and a detectable PTEN
      variant within BRRS.
  - reference: PMID:39256443
    reference_title: A systematic review of Bannayan - Riley - Ruvalcaba syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lipomas were mentioned in more than half of the cases (18/33), and the second most common lesion was gastrointestinal polyps (16/33)."
    explanation: >-
      BRRS-specific frequency for lipomas from the pediatric systematic review, and the
      companion figure for gastrointestinal polyps.
- category: Dermatologic
  name: Penile freckling
  description: >-
    Pigmented macules of the glans penis (genital lentiginosis) are the single most
    specific sign of BRRS. Unlike macrocephaly or lipomas, which are shared across the
    PHTS spectrum, this finding is reported only in BRRS and is therefore of high
    diagnostic value in a male child with macrocephaly and polyposis. Important timing
    caveat: the macules typically appear peripubertally rather than in infancy, so their
    ABSENCE in a young child does not argue against the diagnosis, and the sign is
    sex-limited. The `diagnostic: true` flag therefore means high specificity when present,
    not screening sensitivity.
  phenotype_term:
    preferred_term: Pigmented macules of the glans penis
    term:
      id: HP:0031447
      label: Penile freckling
  diagnostic: true
  evidence:
  - reference: PMID:20301661
    reference_title: PTEN Hamartoma Tumor Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "BRRS is a congenital disorder characterized by macrocephaly, intestinal hamartomatous polyposis, lipomas, and pigmented macules of the glans penis."
    explanation: GeneReviews names pigmented macules of the glans penis as a defining BRRS feature.
  - reference: PMID:10400993
    reference_title: PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pigmented macules of the glans penis, delayed motor development and neonatal or infant onset are noted only in BRR."
    explanation: >-
      Directly supports the diagnostic specificity claim: this sign is restricted to BRRS
      within the PHTS spectrum.
  - reference: PMID:39256443
    reference_title: A systematic review of Bannayan - Riley - Ruvalcaba syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pigmented penile macules were described in the majority of male reports (21/28)."
    explanation: >-
      BRRS-specific frequency in male cases. Note this sign is sex-limited, which is also
      why the same review found a male predominance among published cases; no
      whole-cohort frequency band is asserted here for that reason.
- category: Neurologic
  name: Global developmental delay
  description: >-
    Developmental delay affecting motor, speech, and language domains is common in BRRS
    and, together with macrocephaly, is a leading reason for presentation in childhood.
    Delayed motor development in particular was historically noted only in BRRS and not
    in Cowden syndrome.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:28526761
    reference_title: A retrospective chart review of the features of PTEN hamartoma tumour syndrome in children.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Macrocephaly (average head circumference of + 5.7  SD) with developmental delay, ID and/or ASD were the most common presenting signs/symptoms (66 %)."
    explanation: >-
      Establishes developmental delay as part of the leading presentation in a pediatric
      PHTS cohort.
  - reference: PMID:34983360
    reference_title: "Behavioural and psychological features of PTEN mutations: a systematic review of the literature and meta-analysis of the prevalence of autism spectrum disorder characteristics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Intellectual disability and developmental delay (global, motor and speech and language) were also reported frequently."
    explanation: >-
      Systematic review confirming that global, motor, and speech-language delay are
      frequent in constitutional PTEN variant carriers.
- category: Neurobehavioral
  name: Autism
  description: >-
    Autism spectrum characteristics are substantially over-represented in individuals
    with germline PTEN variants. A meta-analysis of PHTS cohorts estimated a pooled
    prevalence of about 25%, and PTEN testing is recommended in children presenting with
    macrocephaly together with autism spectrum disorder.
  phenotype_term:
    preferred_term: Autism spectrum characteristics
    term:
      id: HP:0000717
      label: Autism
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:34983360
    reference_title: "Behavioural and psychological features of PTEN mutations: a systematic review of the literature and meta-analysis of the prevalence of autism spectrum disorder characteristics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Meta-analysis using a random effects model estimated pooled prevalence of ASD characteristics at 25% (95% CI 16-33%), although this should be interpreted cautiously due to possible biases in existing literature."
    explanation: >-
      Provides the quantitative pooled prevalence (25%) that sets the OCCASIONAL band
      (5-29%). Documenting a deliberate band choice: single cohorts report higher figures
      that would fall in FREQUENT (the pediatric PHTS chart review cited below reports 50%
      ASD diagnoses), but the pooled random-effects estimate across 14 studies is preferred
      here as the less ascertainment-biased summary, and its confidence interval of 16-33%
      sits mostly within OCCASIONAL.
  - reference: PMID:28526761
    reference_title: A retrospective chart review of the features of PTEN hamartoma tumour syndrome in children.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It is recognised that 5% - 10 % of children with macrocephaly and autism spectrum disorder (ASD) and/or intellectual disability (ID) have a heterozygous pathogenic mutation in the PTEN tumour suppressor gene that is associated with PTEN hamartoma tumour syndrome."
    explanation: >-
      Supports the reciprocal clinical rule that macrocephaly plus ASD should prompt PTEN
      testing.
- category: Neurologic
  name: Intellectual disability
  description: >-
    Intellectual disability of variable severity occurs in a substantial minority of
    individuals with BRRS. Early recognition matters because it drives developmental
    support needs independently of the tumor-surveillance agenda.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:10400993
    reference_title: PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Additional features observed in BRR, which may also occur in a minority of CS patients, include Hashimoto's thyroiditis, vascular malformations and mental retardation."
    explanation: >-
      Documents cognitive impairment (reported using the era's terminology) as a recognized
      BRRS feature.
  - reference: PMID:34983360
    reference_title: "Behavioural and psychological features of PTEN mutations: a systematic review of the literature and meta-analysis of the prevalence of autism spectrum disorder characteristics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Intellectual disability and developmental delay (global, motor and speech and language) were also reported frequently."
    explanation: Systematic review confirming intellectual disability is frequently reported in PTEN carriers.
- category: Neurologic
  name: Hypotonia
  description: >-
    Central hypotonia with associated motor delay is a common early BRRS finding,
    contributing to feeding and gross-motor difficulties in infancy. It forms part of the
    cognitive and motor dysfunction described in the original clinical delineation of the
    syndrome.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:29263846
    reference_title: Germline TTN variants are enriched in PTEN-wildtype Bannayan-Riley-Ruvalcaba syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Muscle weakness and hypotonia cause affected BRRS infants to appear"
    explanation: >-
      Names hypotonia explicitly in BRRS infants and links it to the delayed motor
      development curated in this entry.
  - reference: PMID:39256443
    reference_title: A systematic review of Bannayan - Riley - Ruvalcaba syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "some PTEN pathogenic variant carriers can suffer from muscle hypotonia, which is associated with motor delay"
    explanation: >-
      BRRS systematic review naming muscle hypotonia and its association with motor delay.
      The hedged wording ("some") is why no frequency band is asserted.
  - reference: PMID:9352843
    reference_title: Localization of the Bannayan-Riley-Ruvalcaba syndrome gene to chromosome 10q23.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bannayan-Riley-Ruvalcaba syndrome is a congenital syndrome with characteristic features of macrocephaly, cognitive and motor dysfunction, subcutaneous and visceral lipomas and hemangiomas, and intestinal juvenile polyposis."
    explanation: >-
      Recorded as PARTIAL because the source documents motor dysfunction as a core BRRS
      feature without naming hypotonia specifically; it supports the motor-impairment
      phenotype but does not by itself establish the tone abnormality.
- category: Cardiovascular
  name: Hemangioma
  description: >-
    Cutaneous and visceral hemangiomas are part of the original BRRS description and
    contribute to the syndrome's vascular burden. Historical synonyms for the disorder
    explicitly reference multiple hemangiomas alongside lipomas.
  phenotype_term:
    preferred_term: Hemangioma
    term:
      id: HP:0001028
      label: Hemangioma
  evidence:
  - reference: PMID:9352843
    reference_title: Localization of the Bannayan-Riley-Ruvalcaba syndrome gene to chromosome 10q23.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bannayan-Riley-Ruvalcaba syndrome is a congenital syndrome with characteristic features of macrocephaly, cognitive and motor dysfunction, subcutaneous and visceral lipomas and hemangiomas, and intestinal juvenile polyposis."
    explanation: Names subcutaneous and visceral hemangiomas among the characteristic BRRS features.
- category: Cardiovascular
  name: Arteriovenous malformation
  description: >-
    Vascular malformations, including arteriovenous lesions, occur in BRRS and may
    require imaging or intervention. They are shared with the wider PHTS spectrum but
    are more characteristic of the BRRS presentation.
  phenotype_term:
    preferred_term: Arteriovenous malformation
    term:
      id: HP:0100026
      label: Arteriovenous malformation
  evidence:
  - reference: PMID:39256443
    reference_title: A systematic review of Bannayan - Riley - Ruvalcaba syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Another frequent finding was vascular abnormalities, namely, hemangiomas (8/33) and AVMs (6/33)."
    explanation: >-
      Names arteriovenous malformations specifically (not merely "vascular malformations")
      and gives the BRRS report-level frequency, 6 of 33.
  - reference: PMID:39256443
    reference_title: A systematic review of Bannayan - Riley - Ruvalcaba syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Notably, AVMs can occur in the CNS and carry a potential risk of bleeding and complications related to mass effects"
    explanation: >-
      Supports the clinical significance of AVMs in BRRS, including the CNS location that
      drives imaging and intervention decisions.
  - reference: PMID:10400993
    reference_title: PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Additional features observed in BRR, which may also occur in a minority of CS patients, include Hashimoto's thyroiditis, vascular malformations and mental retardation."
    explanation: >-
      Recorded as PARTIAL because this source establishes vascular malformations broadly as a
      BRRS feature but does not specify the arteriovenous subtype that this phenotype is
      bound to.
- category: Endocrine
  name: Hashimoto thyroiditis
  description: >-
    Autoimmune (Hashimoto) thyroiditis and other benign thyroid pathology are
    over-represented in BRRS. Thyroid abnormalities are age-dependent and may be absent
    at first diagnosis, which is why annual thyroid ultrasound is recommended from the
    time of diagnosis in childhood.
  phenotype_term:
    preferred_term: Hashimoto thyroiditis
    term:
      id: HP:0000872
      label: Hashimoto thyroiditis
  evidence:
  - reference: PMID:10400993
    reference_title: PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Additional features observed in BRR, which may also occur in a minority of CS patients, include Hashimoto's thyroiditis, vascular malformations and mental retardation."
    explanation: Documents Hashimoto thyroiditis as a recognized BRRS feature.
  - reference: PMID:28526761
    reference_title: A retrospective chart review of the features of PTEN hamartoma tumour syndrome in children.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical features included dermatological findings (66 %), gastrointestinal (GI) symptoms (34 %), ASD diagnosis (50 %), abnormal brain imaging (53 % of those examined) and abnormal thyroid imaging (26 %)."
    explanation: >-
      Recorded as PARTIAL because abnormal thyroid imaging in 26% of a pediatric PHTS cohort
      establishes that thyroid involvement is already present in childhood, but does not
      itself establish autoimmune thyroiditis as the pathology.
- category: Neoplastic
  name: Breast carcinoma
  description: >-
    Female carriers of germline PTEN variants face the highest organ-specific cancer risk
    of the syndrome. Estimates are cohort-dependent: the prospective International Cowden
    Consortium series gives a lifetime risk of about 85%, while a review across four
    independent PHTS cohorts gives a range of 67% to 85% at age 60-70. Both are drawn from
    strongly ascertained cohorts. This risk applies to PTEN-positive BRRS by allelism with
    Cowden syndrome and is realized in adulthood.
  phenotype_term:
    preferred_term: Breast carcinoma
    term:
      id: HP:0003002
      label: Breast carcinoma
  evidence:
  - reference: PMID:20301661
    reference_title: PTEN Hamartoma Tumor Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The lifetime risk of developing breast cancer is 85%, with an average age of diagnosis between 38 and 46 years."
    explanation: >-
      GeneReviews gives the lifetime breast cancer risk and the adult age range at which it
      is realized.
  - reference: PMID:22252256
    reference_title: Lifetime cancer risks in individuals with germline PTEN mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Estimated lifetime risks were, respectively, 85.2% (95% CI, 71.4%-99.1%), 35.2% (19.7%-50.7%), 28.2% (17.1%-39.3%), 9.0% (3.8%-14.1%), 33.6% (10.4%-56.9%), and 6% (1.6%-9.4%)."
    explanation: >-
      Prospective PHTS cohort reporting the 85.2% lifetime breast cancer risk, the first
      value in the ordered list of breast, thyroid, endometrium, colorectum, kidney, and
      melanoma.
  - reference: PMID:33140411
    reference_title: A review on age-related cancer risks in PTEN hamartoma tumor syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The tumor spectrum included female breast cancer (CLTRs including sex-specific estimates at age 60-70: 67% to 85%), endometrium cancer (19% to 28%), thyroid cancer (6% to 38%), renal cancer (2% to 24%), colorectal cancer (9% to 32%), and melanoma (0% to 6%)."
    explanation: >-
      Gives the cross-cohort ranges for every cancer site curated in this entry, which is why
      the descriptions frame risk as a range rather than a single point estimate.
- category: Neoplastic
  name: Thyroid carcinoma
  description: >-
    Thyroid carcinoma, typically follicular and never medullary, carries a lifetime risk
    of roughly 35% in germline PTEN carriers. It is the earliest-onset malignancy in the
    spectrum, which is why thyroid ultrasound surveillance begins in childhood.
  phenotype_term:
    preferred_term: Thyroid carcinoma
    term:
      id: HP:0002890
      label: Thyroid carcinoma
  evidence:
  - reference: PMID:20301661
    reference_title: PTEN Hamartoma Tumor Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The lifetime risk for thyroid cancer (usually follicular, rarely papillary, but never medullary thyroid cancer) is approximately 35%."
    explanation: GeneReviews gives the thyroid cancer lifetime risk and its histologic pattern.
  - reference: PMID:20301661
    reference_title: PTEN Hamartoma Tumor Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Yearly thyroid ultrasound from the time of diagnosis (earliest reported at age 7 years) and skin check with physical examination."
    explanation: >-
      Supports the childhood onset of thyroid malignancy risk, with the earliest reported
      case at age 7, motivating pediatric thyroid surveillance.
- category: Neoplastic
  name: Endometrial carcinoma
  description: >-
    Endometrial carcinoma risk approaches 28% in germline PTEN carriers, prompting
    consideration of endometrial surveillance in adult women.
  phenotype_term:
    preferred_term: Endometrial carcinoma
    term:
      id: HP:0012114
      label: Endometrial carcinoma
  evidence:
  - reference: PMID:20301661
    reference_title: PTEN Hamartoma Tumor Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The risk for endometrial cancer may approach 28%."
    explanation: GeneReviews gives the endometrial cancer lifetime risk estimate.
- category: Neoplastic
  name: Renal cell carcinoma
  description: >-
    Renal cell carcinoma, predominantly of papillary histology, occurs with a lifetime
    risk of approximately 34%, motivating biennial renal imaging from age 40.
  phenotype_term:
    preferred_term: Renal cell carcinoma
    term:
      id: HP:0005584
      label: Renal cell carcinoma
  evidence:
  - reference: PMID:20301661
    reference_title: PTEN Hamartoma Tumor Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The lifetime risk for renal cell cancer (predominantly of papillary histology) is 34%."
    explanation: GeneReviews gives the renal cell carcinoma lifetime risk and histologic pattern.
- category: Neoplastic
  name: Colon cancer
  description: >-
    Colorectal carcinoma risk is elevated several-fold over the general population,
    arising against the background of hamartomatous polyposis. Reported cumulative
    estimates vary with cohort and ascertainment, and colorectal screening is recommended
    from age 35 to 40.
  phenotype_term:
    preferred_term: Colorectal carcinoma
    term:
      id: HP:0003003
      label: Colon cancer
  evidence:
  - reference: PMID:22672595
    reference_title: Is colorectal surveillance indicated in patients with PTEN mutations?
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Benign gastrointestinal lesions are common in PTEN mutation carriers, and a three- to four-fold increased lifetime risk of colorectal cancer compared with the general population may exist."
    explanation: >-
      Multinational PTEN-carrier cohort quantifying the relative colorectal cancer risk that
      justifies colonoscopic surveillance.
- category: Neoplastic
  name: Melanoma
  description: >-
    Cutaneous melanoma occurs at modestly increased frequency in germline PTEN carriers,
    supporting routine dermatologic examination as part of surveillance.
  phenotype_term:
    preferred_term: Melanoma
    term:
      id: HP:0002861
      label: Melanoma
  evidence:
  - reference: PMID:22252256
    reference_title: Lifetime cancer risks in individuals with germline PTEN mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lifetime risks for a variety of cancers, now extending to colorectal cancer, kidney cancer, and melanoma, are increased in patients with PTEN mutations."
    explanation: >-
      Establishes melanoma as part of the confirmed germline PTEN cancer spectrum in a
      prospective cohort.
genetic:
- name: PTEN
  notes: >-
    Heterozygous germline loss-of-function variants in PTEN (10q23) cause BRRS. The
    mutation spectrum includes nonsense, frameshift, missense, and splice variants as
    well as large deletions, and is indistinguishable from that seen in Cowden syndrome.
    Detection rate is ascertainment-dependent and must be read with that caveat: the
    classic clinically ascertained BRRS series found variants in 60% of cases, whereas a
    2024 systematic review of published pediatric cases found 75/83 (90%) — the latter
    reflects modern practice in which patients are increasingly defined by having the
    variant. The lower classic figure is the relevant one when asking whether a clinically
    diagnosed child without a detectable variant still has BRRS, and on that reading a
    negative PTEN result does not exclude the clinical diagnosis.
  gene_term:
    preferred_term: PTEN
    term:
      id: hgnc:9588
      label: PTEN
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  evidence:
  - reference: PMID:34754688
    reference_title: "Diffuse Gastrointestinal Polyposis in Bannayan-Riley-Ruvalcaba Syndrome: A Rare Phenotype Among Phosphatase and Tensin Homolog Hamartoma Tumor Syndromes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bannayan-Riley-Ruvalcaba syndrome (BRRS) is a rare genetic disorder caused by germline mutations in the phosphatase and tensin homolog (PTEN) gene."
    explanation: Directly assigns germline PTEN variants as the cause of BRRS.
  - reference: PMID:10400993
    reference_title: PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mutations were identified in 26 of 43 (60%) BRR cases."
    explanation: >-
      Establishes the approximately 60% germline PTEN detection rate in a dedicated BRRS
      cohort.
  - reference: PMID:10400993
    reference_title: PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Among CS, BRR and BRR/CS overlap families that are PTEN mutation positive, the mutation spectra appear similar."
    explanation: >-
      Supports the claim that the BRRS mutation spectrum is not distinguishable from that of
      Cowden syndrome.
  - reference: PMID:10353779
    reference_title: Phenotypic findings of Cowden syndrome and Bannayan-Zonana syndrome in a family associated with a single germline mutation in PTEN.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We have identified a germline mutation, R335X, in PTEN in a family consisting of two female members with the phenotypic findings of CS and two male members with the phenotypic findings of BZS."
    explanation: >-
      A single PTEN nonsense variant segregating with both Cowden and BRRS phenotypes in one
      family, the key intrafamilial evidence for allelism.
- name: TTN
  notes: >-
    TTN (titin) is a candidate predisposing locus in PTEN-wildtype BRRS, and is the most
    substantive lead for the roughly 40% of clinically diagnosed BRRS cases without a PTEN
    variant. Rare germline TTN missense variants were found in about a third of
    exome-sequenced PTEN-wildtype classic BRRS patients, and one I-band variant produced
    loss of
    contact inhibition in edited cells, suggesting a PI3K-independent route to the same
    overgrowth output. This is explicitly a candidate association, not an established
    disease gene, and is curated as SUSCEPTIBILITY rather than CAUSATIVE. The overlap of
    BRRS features with known titinopathy phenotypes (joint hyperextensibility, muscle
    hypotonia, delayed psychomotor development) is a supporting but non-decisive
    observation.
  gene_term:
    preferred_term: TTN
    term:
      id: hgnc:12403
      label: TTN
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  evidence:
  - reference: PMID:29263846
    reference_title: Germline TTN variants are enriched in PTEN-wildtype Bannayan-Riley-Ruvalcaba syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We exome-sequenced 35 unrelated PTEN-wildtype patients with classic presentation of BRRS and identified TTN germline missense variants in 12/35 (34%) patients."
    explanation: >-
      The primary human genetic observation: rare TTN missense variants in about a third of
      PTEN-wildtype classic BRRS patients.
  - reference: PMID:29263846
    reference_title: Germline TTN variants are enriched in PTEN-wildtype Bannayan-Riley-Ruvalcaba syndrome.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "suggested lack of contact inhibition in mutant cells"
    explanation: >-
      Cell-based functional support for one TTN variant. Recorded as PARTIAL with
      evidence_source IN_VITRO because it is an edited-cell phenotype, not a demonstration
      of the human disease mechanism.
  - reference: PMID:29263846
    reference_title: Germline TTN variants are enriched in PTEN-wildtype Bannayan-Riley-Ruvalcaba syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "our observations suggest TTN as a candidate predisposing gene in classic PTEN-wildtype BRRS patients, perhaps suggesting this syndrome join the growing list of Titinopathies"
    explanation: >-
      The authors' own framing as a candidate gene, which is why this is curated as
      SUSCEPTIBILITY rather than CAUSATIVE.
diagnosis:
- name: PTEN Molecular Genetic Testing
  description: >-
    Definitive diagnosis rests on identifying a heterozygous germline PTEN pathogenic
    variant. Because a substantial minority of clinically diagnosed BRRS cases have no
    detectable PTEN variant, a negative result does not overturn a clinical diagnosis, and
    such individuals are still generally managed with surveillance.

    Testing is tiered, and sequencing alone is not sufficient. Coding-region sequencing is
    the first step, but contiguous-gene and whole/multi-exon deletions at 10q23 are invisible
    to it and require deletion/duplication analysis (MLPA) or chromosomal microarray — the
    10q23 PTEN-plus-BMPR1A deletion subtype curated in this entry is found only that way.
    Assay design must also contend with the processed pseudogene PTENP1 on chromosome 9,
    which cross-amplifies with PTEN.
  evidence:
  - reference: PMID:18510548
    reference_title: Variable phenotypes associated with 10q23 microdeletions involving the PTEN and BMPR1A genes.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The sizes of the deletions were analyzed using single nucleotide polymorphism array analysis."
    explanation: >-
      Supports the need for array-based rather than sequencing-only testing to detect the
      10q23 contiguous deletions described in this section.
  - reference: PMID:21177507
    reference_title: Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Other mechanisms of loss of function such as hypermethylation, which should result in underexpression of PTEN or of KILLIN, a novel tumor suppressor transcribed in the opposite direction, may account for the remainder of Cowden syndrome and Cowden-like syndro"
    explanation: >-
      Supports germline promoter hypermethylation as a testable non-sequence mechanism in
      mutation-negative cases, which is why the workup does not stop at sequencing.
  - reference: PMID:20301661
    reference_title: PTEN Hamartoma Tumor Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of PHTS is established in a proband by identification of a heterozygous germline PTEN pathogenic variant on molecular genetic testing."
    explanation: GeneReviews states the molecular basis of establishing the PHTS diagnosis.
- name: Clinical Recognition in Childhood
  description: >-
    BRRS is recognized clinically in a child with macrocephaly plus some combination of
    hamartomatous gastrointestinal polyposis, multiple lipomas, and pigmented macules of
    the glans penis, often alongside developmental delay or autism spectrum features.
    Because dermatologic, gastrointestinal, and thyroid findings are age-dependent, their
    absence at first assessment does not exclude the diagnosis.
  evidence:
  - reference: PMID:37900693
    reference_title: Clinical Guidelines for Diagnosis and Management of Cowden Syndrome/PTEN Hamartoma Tumor Syndrome in Children and Adults-Secondary Publication.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This syndrome is occasionally diagnosed in childhood due to the occurrence of multiple gastrointestinal polyps, autism spectrum disorders, and intellectual disability."
    explanation: >-
      Guideline statement describing the childhood route to diagnosis that characterizes the
      BRRS presentation.
  - reference: PMID:28526761
    reference_title: A retrospective chart review of the features of PTEN hamartoma tumour syndrome in children.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Dermatological, GI and thyroid abnormalities are age dependent and may not be present at the time of diagnosis, requiring regular monitoring and medical surveillance."
    explanation: >-
      Supports the caution that age-dependent features may be absent at initial pediatric
      assessment.
treatments:
- name: Lifelong Cancer Surveillance
  description: >-
    The central management intervention. Because PTEN-positive BRRS carries the same
    cancer burden as Cowden syndrome, surveillance is identical and lifelong: annual
    thyroid ultrasound and skin examination from the time of diagnosis in childhood;
    in adults, annual thyroid ultrasound and dermatologic evaluation; from age 30 in
    women, breast screening with consideration of endometrial assessment from age 35;
    colonoscopy from age 35 with intervals set by polyp burden; and biennial renal
    imaging from age 40. Family history of early-onset cancer should pull screening
    earlier by 5 to 10 years.
  treatment_term:
    preferred_term: cancer surveillance
    term:
      id: NCIT:C15406
      label: Cancer Screening
  evidence:
  - reference: PMID:10400993
    reference_title: PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thus, PTEN mutation-positive CS and BRR may be different presentations of a single syndrome and, hence, both should receive equal attention with respect to cancer surveillance."
    explanation: >-
      The primary justification for applying full Cowden-equivalent surveillance to
      PTEN-positive BRRS.
  - reference: PMID:20301661
    reference_title: PTEN Hamartoma Tumor Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Yearly thyroid ultrasound from the time of diagnosis (earliest reported at age 7 years) and skin check with physical examination."
    explanation: GeneReviews pediatric surveillance recommendation, directly applicable to childhood-diagnosed BRRS.
  - reference: PMID:20301661
    reference_title: PTEN Hamartoma Tumor Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Men and women. Colonoscopy beginning at age 35 years with frequency dependent on degree of polyposis identified or family history of early-onset colon cancer (before age 40); biennial (every 2 years) renal imaging (CT or MRI preferred) beginning at age 40 years."
    explanation: GeneReviews colorectal and renal surveillance schedule.
  - reference: PMID:20301661
    reference_title: PTEN Hamartoma Tumor Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Those with a family history of a particular cancer type at an early age. Consider initiating screening 5 to 10 years prior to the youngest age of diagnosis in the family."
    explanation: GeneReviews guidance for family-history-driven earlier surveillance.
  - reference: PMID:32533092
    reference_title: Cancer Surveillance Guideline for individuals with PTEN hamartoma tumour syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Recommendations were put forward for surveillance for breast, thyroid and renal cancers. Limited recommendations were developed for other sites including endometrial, colon and skin."
    explanation: >-
      Recorded as PARTIAL because this European guideline supports strong recommendations
      only for breast, thyroid, and renal surveillance, and explicitly describes the
      endometrial, colon, and skin recommendations as limited.
  - reference: PMID:39256443
    reference_title: A systematic review of Bannayan - Riley - Ruvalcaba syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "As targeted treatment is still lacking, symptom relief and long-term surveillance remain the main management strategies."
    explanation: >-
      BRRS-specific systematic review confirming that surveillance plus symptom-directed
      care, rather than any disease-modifying therapy, is the management mainstay.
- name: Gastrointestinal Polyp Management
  description: >-
    Symptomatic or large hamartomatous polyps are managed endoscopically with
    polypectomy, with colonoscopic surveillance intervals determined by polyp burden.
    Benign gastrointestinal lesions are common enough in PTEN carriers that structured
    colorectal screening is recommended rather than symptom-driven assessment alone.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: endoscopic polypectomy
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  evidence:
  - reference: PMID:22672595
    reference_title: Is colorectal surveillance indicated in patients with PTEN mutations?
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Colorectal screening of patients with germline PTEN mutations is recommended, starting at age 40 years."
    explanation: >-
      Supports structured colorectal screening in PTEN carriers. Note this cohort proposes
      age 40, whereas GeneReviews recommends starting at 35.
- name: Symptomatic Management of Hamartomatous Lesions
  description: >-
    Lipomas, vascular lesions, and other benign manifestations are treated the same way
    as their sporadic counterparts, with excision reserved for lesions causing pain,
    functional impairment, deformity, or diagnostic uncertainty rather than performed
    prophylactically.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: surgical excision
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  evidence:
  - reference: PMID:20301661
    reference_title: PTEN Hamartoma Tumor Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment for the benign and malignant manifestations of PHTS is the same as for their sporadic counterparts."
    explanation: GeneReviews establishes the principle of treating manifestations as for sporadic disease.
  - reference: PMID:20301661
    reference_title: PTEN Hamartoma Tumor Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cutaneous lesions should be excised only if malignancy is suspected or symptoms (e.g., pain, deformity, increased scarring) are significant."
    explanation: GeneReviews supports restricting excision to symptomatic or suspicious lesions.
- name: Developmental and Behavioral Support
  description: >-
    Because developmental delay, intellectual disability, and autism spectrum
    characteristics are core to the BRRS presentation, early developmental assessment and
    intervention (speech, motor, and educational support) is a management priority
    independent of the cancer-surveillance agenda.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: rehabilitation
    term:
      id: NCIT:C15315
      label: Rehabilitation
  evidence:
  - reference: PMID:28526761
    reference_title: A retrospective chart review of the features of PTEN hamartoma tumour syndrome in children.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Early paediatric diagnosis is important for institution of medical and developmental surveillance as well as for testing other at- risk family members."
    explanation: >-
      Supports developmental surveillance and support as an explicit goal of early pediatric
      diagnosis.
- name: mTOR Inhibitor Therapy
  description: >-
    Everolimus targets the mTOR overactivity that follows PTEN loss, giving a direct
    mechanistic rationale. A 6-month phase II randomized placebo-controlled trial in 46
    individuals with PHTS aged 5 to 45 found the drug tolerable but did not meet its
    primary neurocognitive endpoint, with gastrointestinal adverse events more common on
    treatment. mTOR inhibition therefore remains investigational for the
    neurodevelopmental features of BRRS and is not routine care.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: mTOR inhibitor pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: everolimus
      term:
        id: CHEBI:68478
        label: everolimus
  target_mechanisms:
  - target: PIP3 Accumulation and PI3K-AKT-mTOR Hyperactivation
    treatment_effect: INHIBITS
    description: >-
      Everolimus inhibits mTORC1 downstream of the PIP3/AKT node, partially offsetting the
      signaling excess caused by PTEN loss.
  evidence:
  - reference: PMID:35594551
    reference_title: A randomized controlled trial of everolimus for neurocognitive symptoms in PTEN hamartoma tumor syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PTEN hamartoma tumor syndrome (PHTS) is a complex neurodevelopmental disorder characterized by mechanistic target of rapamycin (mTOR) overactivity."
    explanation: Establishes the mechanistic rationale for mTOR inhibition in PHTS.
  - reference: PMID:35594551
    reference_title: A randomized controlled trial of everolimus for neurocognitive symptoms in PTEN hamartoma tumor syndrome.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "Changes in the primary endpoint between groups from baseline to Month 6 were not apparent"
    explanation: >-
      Recorded as REFUTE for the claim of neurocognitive efficacy. The randomized trial's
      primary endpoint was null, which is why this treatment is curated as investigational
      rather than established.
  - reference: PMID:35594551
    reference_title: A randomized controlled trial of everolimus for neurocognitive symptoms in PTEN hamartoma tumor syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Gastrointestinal adverse events were more common in the everolimus group"
    explanation: Documents the principal treatment-emergent toxicity signal in the trial.
- name: Sirolimus for Vascular Anomalies
  description: >-
    Sirolimus (rapamycin) is the lesion-directed mTOR-inhibitor use in BRRS, distinct from
    the neurocognitive indication that the everolimus trial tested and missed. It is used
    off-label for symptomatic vascular anomalies when other treatments have failed, and the
    BRRS-specific published experience is a single pediatric case in the 2024 systematic
    review. Evidence is therefore anecdotal, and this is curated as an off-label option
    under investigation rather than standard care.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: mTOR inhibitor pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: sirolimus
      term:
        id: CHEBI:9168
        label: sirolimus
  target_mechanisms:
  - target: PTEN Hamartoma of Soft Tissue Formation
    treatment_effect: INHIBITS
    description: >-
      Sirolimus acts on the lesion itself: mTORC1 inhibition shrinks the intramuscular
      fat-and-vessel overgrowth, which is why the reported benefit is lesion size and
      symptom relief rather than a systemic disease-modifying effect.
  - target: PIP3 Accumulation and PI3K-AKT-mTOR Hyperactivation
    treatment_effect: INHIBITS
    description: >-
      The upstream pharmacological rationale: sirolimus inhibits mTORC1 downstream of the
      PIP3/AKT node.
  evidence:
  - reference: PMID:39256443
    reference_title: A systematic review of Bannayan - Riley - Ruvalcaba syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "mTOR inhibitors have been investigated in patients with vascular anomalies when previous treatments were ineffective"
    explanation: >-
      Establishes the lesion-directed indication. PARTIAL because it describes an
      investigational, salvage-setting use rather than established efficacy.
  - reference: PMID:39256443
    reference_title: A systematic review of Bannayan - Riley - Ruvalcaba syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "only one study reported the use of rapamycin"
    explanation: >-
      Quantifies how thin the BRRS-specific evidence is: a single report among 33 reviewed
      articles, which is why this is curated as anecdotal rather than standard care.
  - reference: PMID:39256443
    reference_title: A systematic review of Bannayan - Riley - Ruvalcaba syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There is no established standard treatment for PHTS patients"
    explanation: >-
      Confirms the absence of an established standard therapy in PHTS, the framing under
      which any mTOR-inhibitor use in BRRS should be read.
- name: Genetic Counseling and Cascade Testing
  description: >-
    Genetic counseling covers the autosomal dominant 50% transmission risk, the
    variable expressivity that lets one PTEN variant produce BRRS in one relative and
    Cowden syndrome in another, and the value of predictive testing in at-risk relatives
    so that carriers can enter surveillance.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:20301661
    reference_title: PTEN Hamartoma Tumor Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "When a PTEN pathogenic variant has been identified in a proband, molecular genetic testing of asymptomatic at-risk relatives can identify those who have the family-specific pathogenic variant and warrant ongoing surveillance."
    explanation: GeneReviews supports cascade testing of at-risk relatives to direct surveillance.
  - reference: PMID:10353779
    reference_title: Phenotypic findings of Cowden syndrome and Bannayan-Zonana syndrome in a family associated with a single germline mutation in PTEN.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "To our knowledge, this is the first report that shows the presence of separate subjects with CS and with BZS in a single family associated with a single germline PTEN mutation."
    explanation: >-
      Supports counseling about intrafamilial variable expressivity: the same variant can
      produce either BRRS or Cowden syndrome in different relatives.
differential_diagnoses:
- name: Cowden Syndrome
  description: >-
    The adult-presenting allelic PHTS phenotype. Distinguished by trichilemmomas and
    mucocutaneous papillomatous papules with presentation in the late 20s, rather than
    the congenital macrocephaly, polyposis, lipoma, and genital lentiginosis pattern of
    BRRS. The distinction is clinical and developmental, not molecular: both arise from
    germline PTEN variants and both require the same cancer surveillance.
  evidence:
  - reference: PMID:10400993
    reference_title: PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pigmented macules of the glans penis, delayed motor development and neonatal or infant onset are noted only in BRR."
    explanation: Gives the specific features that separate BRRS from Cowden syndrome clinically.
- name: Juvenile Polyposis Syndrome
  description: >-
    Shares hamartomatous gastrointestinal polyposis with BRRS and was historically
    considered a possible variant of it, but is caused by SMAD4 or BMPR1A variants and
    lacks macrocephaly, lipomas, and genital lentiginosis.
  evidence:
  - reference: PMID:9352843
    reference_title: Localization of the Bannayan-Riley-Ruvalcaba syndrome gene to chromosome 10q23.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It has been suggested that Bannayan-Riley-Ruvalcaba syndrome may be a variant of juvenile polyposis coli because of the shared features of intestinal juvenile polyps."
    explanation: >-
      Documents the historical diagnostic confusion between BRRS and juvenile polyposis based
      on shared polyp histology.
discussions:
- discussion_id: gap_brrs_pediatric_ascertained_cancer_risk
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    What is the actual, prospectively measured cancer risk in individuals ascertained as
    BRRS in childhood, as opposed to risk inferred from adult, cancer-ascertained Cowden
    syndrome cohorts?
  attaches_to:
  - pathophysiology#Lifelong Multiorgan Cancer Predisposition
  rationale: >-
    The cancer surveillance imposed on children diagnosed with BRRS rests on allelism with
    Cowden syndrome rather than on direct BRRS-cohort incidence data. The original BRRS
    delineation explicitly noted that malignancy had not been formally documented in BRRS,
    and contemporary reviews flag that existing PHTS risk estimates come from strongly
    ascertained, mostly adult cohorts with an acknowledged absence of pediatric research.
    If BRRS-ascertained carriers have materially different risk, current pediatric
    surveillance may be either over- or under-calibrated.
  proposed_experiments:
  - experiment_id: brrs-prospective-pediatric-cohort
    name: Prospective pediatric BRRS cancer-incidence cohort
    description: >-
      A prospective, multicenter cohort of individuals ascertained in childhood by BRRS
      clinical criteria and followed into adulthood, reporting age- and site-specific
      cancer incidence separately for PTEN-positive and PTEN-negative participants.
  evidence:
  - reference: PMID:33140411
    reference_title: A review on age-related cancer risks in PTEN hamartoma tumor syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Although these estimates provide guidance for clinical care, discrepancies between studies, sample sizes, retrospective designs, strongly ascertained cases, and lack of pediatric research emphasizes that data should be interpreted with great caution."
    explanation: Explicitly identifies the absence of pediatric data and ascertainment bias as the gap.
  - reference: PMID:31609537
    reference_title: "PTEN Hamartoma tumor syndrome in childhood: A review of the clinical literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We acknowledge the limited understanding of the natural history of childhood-onset PHTS as a cancer predisposition syndrome and present a summary of important management considerations."
    explanation: >-
      A pediatric-focused review stating directly that the natural history of childhood-onset
      PHTS as a cancer predisposition syndrome is poorly understood.
- discussion_id: gap_brrs_mutation_negative_cases
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    What explains the roughly 40% of clinically diagnosed BRRS cases with no detectable
    germline PTEN variant, and do those individuals carry the same cancer risk?
  attaches_to:
  - pathophysiology#Germline PTEN Loss of Function
  rationale: >-
    Only about 60% of classically ascertained BRRS cases have an identifiable germline PTEN
    variant, a lower yield than in Cowden syndrome. Several established explanations account
    for part of the residue and should be excluded before invoking locus heterogeneity:
    large deletions missed by sequencing (recoverable by MLPA or microarray, as in the 10q23
    contiguous-deletion subtype), promoter and deep-intronic variants, somatic mosaicism
    detectable only in lesional tissue, and germline KLLN promoter hypermethylation, which
    silences KILLIN from the promoter PTEN and KLLN share while leaving PTEN transcription
    intact. What remains after all of those is unresolved. Germline TTN missense variants are the leading candidate explanation for
    part of this residue, but remain a candidate association rather than an established
    disease-gene relationship. This directly affects management, because the argument for
    Cowden-equivalent surveillance is anchored on PTEN positivity and does not automatically
    extend to mutation-negative individuals.
  proposed_experiments:
  - experiment_id: brrs-mutation-negative-genomics
    name: Genomic reanalysis of PTEN-mutation-negative BRRS
    description: >-
      Genome sequencing with deep-intronic, promoter, structural-variant, and
      somatic-mosaicism analysis on a cohort of PTEN-mutation-negative clinical BRRS cases,
      paired with long-term cancer outcome follow-up.
  evidence:
  - reference: PMID:10400993
    reference_title: PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mutations were identified in 26 of 43 (60%) BRR cases."
    explanation: Quantifies the incomplete molecular yield that defines this gap.
  - reference: PMID:10400993
    reference_title: PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Comparisons between BRR and a previously studied group of 37 CS families suggested an increased likelihood of identifying a germline PTEN mutation in families with either CS alone or both CS and BRR when compared with BRR alone"
    explanation: >-
      Documents that BRRS-alone families have a lower PTEN detection rate, sharpening the
      question of what underlies mutation-negative BRRS.
  - reference: PMID:21177507
    reference_title: Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We sought to address the hypothesis that germline methylation of the 10q23.31 bidirectional promoter CpG island"
    explanation: >-
      Supports germline KLLN promoter hypermethylation at the shared bidirectional promoter
      as one established explanation for PTEN-mutation-negative disease.
  - reference: PMID:29263846
    reference_title: Germline TTN variants are enriched in PTEN-wildtype Bannayan-Riley-Ruvalcaba syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The remaining cases are of unknown genetic etiology."
    explanation: >-
      States the gap directly, and this paper's TTN finding is the leading partial answer to
      it, which is why the evidence is PARTIAL rather than a resolution.
references:
- reference: PMID:20301661
  title: PTEN Hamartoma Tumor Syndrome.
  tags:
  - GeneReviews
notes: >-
  Nosological note. BRRS is retained as a distinct dismech entry rather than folded into
  PTEN_Hamartoma_Tumor_Syndrome or Cowden_Syndrome because its congenital onset,
  neurodevelopmental burden, and diagnostically specific genital lentiginosis define a
  clinically actionable pediatric presentation, even though it is molecularly allelic with
  Cowden syndrome. The entry deliberately foregrounds that allelism, since the single most
  consequential management fact in BRRS is that a childhood diagnosis obligates lifelong
  Cowden-equivalent cancer surveillance. This parallels the existing standalone
  Cowden_Syndrome entry, which is also a PHTS subtype. See issue #869 for the broader
  Cowden/PHTS lumping discussion.
📚

References & Deep Research

References

1
PMID:20301661
PTEN Hamartoma Tumor Syndrome.
No top-level findings curated for this source.

Deep Research

1
Claude Code ▸
Bannayan–Riley–Ruvalcaba Syndrome (BRRS) — Comprehensive Research Report
claude-haiku-4-5-20251001, claude-opus-5[1m] 24 citations 2026-08-03T20:22:44.443204

Bannayan–Riley–Ruvalcaba Syndrome (BRRS) — Comprehensive Research Report

Prepared: 2026-08-03 · Target: kb/disorders/Bannayan-Riley-Ruvalcaba_Syndrome.yaml · Category: Mendelian (autosomal dominant, tumor-predisposition / overgrowth)

⚠️ Curator preflight — read this before you copy anything into YAML

Three things will bite you on this entry, so let's get them out of the way first.

1. Named Entity Confusion risk here is HIGH. BRRS is a triple eponym collision that got merged in the early 1990s — Bannayan–Zonana syndrome, Riley–Smith syndrome, and Ruvalcaba–Myhre–Smith syndrome were three separately-named conditions that turned out to be one thing. Several databases (NORD included) still file it under ruvalcaba-syndrome. Adjacent traps: Riley–Day syndrome (familial dysautonomia, IKBKAP/ELP1 — completely unrelated), Ruvalcaba syndrome (a distinct skeletal-dysplasia eponym), and Cowden syndrome (MONDO:0016063, OMIM:158350), which is the same gene and arguably the same disease but a different KB entity. A deep-research report on "Bannayan syndrome" that talks mostly about breast/thyroid cancer surveillance in adults has probably drifted into Cowden. Run just preflight-dr <report> MONDO:0007924 and expect the canonical gene to be PTEN.

2. Every ontology ID below is a candidate. My local OAK install in this worktree is broken (the Python 3.14 pyhornedowl failure), so I could not verify a single HP/GO/CL/UBERON/CHEBI/NCIT identifier against the authority. Treat the term tables as leads and run just validate-terms before committing. I've flagged the ones I'm least sure about.

3. Quotes marked "verbatim" came from the Europe PMC abstractText field, which is the real abstract — but the reference validator is the arbiter, not me. Run just fetch-reference PMID:xxxxx then just validate-references for each one. Two abstracts I could not retrieve (Marsh 1997 Nat Genet is a letter with no abstract at all; Parisi 2001 has no abstractText in Europe PMC) — do not invent snippets for those.

1. Disease Information

Overview

Bannayan–Riley–Ruvalcaba syndrome is a rare congenital overgrowth and hamartoma disorder, present from birth, defined by the combination of macrocephaly, hamartomatous intestinal polyposis, lipomas, vascular malformations, and pigmented macules of the glans penis (genital lentiginosis), frequently with developmental delay and/or autism spectrum disorder. It is one of the historical clinical presentations now unified under the molecular umbrella of PTEN hamartoma tumor syndrome (PHTS).

The single most consequential fact for a knowledge base: BRRS and Cowden syndrome are, mechanistically, the same disease. Marsh et al. established this in 1999 and Lachlan et al. confirmed it clinically in 2007; GeneReviews now states flatly that the historical phenotypes "represent a unified disease spectrum under the PHTS designation" and that PHTS has no clinical diagnostic criteria of its own — molecular confirmation of a germline PTEN variant is the diagnosis.

Verbatim (PMID:10400993, Marsh et al. 1999, Hum Mol Genet 8:1461–72): "Thus, PTEN mutation-positive CS and BRR may be different presentations of a single syndrome and, hence, both should receive equal attention with respect to cancer surveillance."

BRRS is best understood as the pediatric-onset end of the PHTS spectrum (overgrowth, lipomas, polyps, neurodevelopment) and Cowden syndrome as the adult-onset end (mucocutaneous lesions, breast/thyroid/endometrial cancer), with the same gene and age-related penetrance connecting them.

Identifiers

Resource Identifier Notes
MONDO MONDO:0007924 Verified against EBI OLS4; label "Bannayan-Riley-Ruvalcaba syndrome"; not obsolete
OMIM 153480 Formerly "Bannayan-Zonana syndrome" / "Ruvalcaba-Myhre-Smith syndrome"
Orphanet ORPHA:109
UMLS C0265326
MedGen 78554
DOID DOID:0050657
NCIT NCIT:C3939
SNOMED CT 21984008
ICD-9 759.6
ICD-10-CM MONDO xref says E71.440 — ⚠️ suspicious; most clinical sources use Q85.8 (other phakomatoses, NEC). Verify before curating.
ICD-11 MONDO carries foundation ID 357383447; the practical stem code is in the LD2x hamartoma-syndrome block. Verify.
Gene (HGNC) hgnc:9588 (PTEN); OMIM *601728; UniProt P60484

Synonyms and alternative names

From the MONDO record: BRRS, Bannayan syndrome, Bannayan–Zonana syndrome (BZS), Riley–Smith syndrome, Myhre–Riley–Smith syndrome, Ruvalcaba–Myhre–Smith syndrome (RMSS), "macrocephaly with multiple lipomas and hemangiomas." Also encountered: macrocephaly–multiple lipomas–hemangiomata syndrome, Bannayan–Ruvalcaba–Riley syndrome.

Nature of the evidence base

Overwhelmingly aggregated disease-level and case-level literature, not EHR-derived. The definitive BRRS-specific evidence is a 2024 systematic review of 83 published pediatric cases from 33 articles (PMID:39256443) — all case reports and small series, which the authors explicitly flag as high risk of bias. The large quantitative datasets (cancer risk, GI phenotype) all come from Cowden-ascertained PHTS cohorts (Cleveland Clinic, Dutch/European registries) and must be attributed as PHTS-wide rather than BRRS-specific. A very recent unbiased population signal exists (All of Us / UK Biobank) but is still a preprint as of December 2025.

2. Etiology

Primary cause

Heterozygous germline loss-of-function variants in PTEN (phosphatase and tensin homolog), at 10q23.31. PTEN is a haploinsufficient tumor suppressor; loss of its lipid-phosphatase activity releases the brake on PI3K–AKT–mTOR signaling.

Detection rate in BRRS specifically: ~60% in the classic ascertained series.

Verbatim (PMID:10400993): "In this study, constitutive DNA samples from 43 BRR individuals comprising 16 sporadic and 27 familial cases, 11 of which were families with both CS and BRR, were screened for PTEN mutations. Mutations were identified in 26 of 43 (60%) BRR cases."

The 2024 pediatric systematic review reports a much higher rate — 75/83 (90%) — but that reflects modern ascertainment (patients are increasingly defined by having the variant). The earlier Marsh 1998 series found 4/7 (57%) in Bannayan–Zonana families.

Verbatim (PMID:9467011, Marsh et al. 1998, Hum Mol Genet 7:507–15): "Germline PTEN mutations were identified in four of seven (57%) BZS families studied. Interestingly, none of these mutations was observed in the PTPase core motif."

That last clause is a real, curatable genotype–phenotype observation: BRRS-associated variants were not found in the phosphatase core motif, whereas Cowden variants clustered there (43% of CD mutations in exon 5).

Genetic risk factors beyond PTEN

TTN (titin) — candidate second gene for PTEN-wildtype BRRS. This is the most important non-PTEN finding and is BRRS-specific rather than Cowden-derived.

Verbatim (PMID:29263846, Yehia, Ni & Eng 2017, npj Genom Med 2:37): "We exome-sequenced 35 unrelated PTEN-wildtype patients with classic presentation of BRRS and identified TTN germline missense variants in 12/35 (34%) patients... Rare TTN variants (MAF ≤ 0.0001) are enriched in classic BRRS patients compared to BRRS-like (OR = 2.7, 95% CI 1.21-5.94, p = 1.6 × 10⁻²) and multiple population controls (OR = 2.2, 95% CI 1.01-4.20, p = 4.7 × 10⁻²)."

Functional support: CRISPR-edited cells carrying the I-band variant p.Cys5096Arg showed "increased growth and lack of contact inhibition... associated with increased levels of or phosphorylation of focal adhesion kinase (FAK)." The authors propose BRRS may "join the growing list of Titinopathies." Curation note: this is a candidate gene — use relationship_type: SUSCEPTIBILITY or MODIFIER, not causal, and tag evidence_source: IN_VITRO for the FAK/CRISPR arm.

Other PTEN-wildtype routes (established in Cowden-like, extrapolate cautiously to BRRS): - KLLN/KILLIN germline promoter hypermethylation — 37% of 123 PTEN-mutation-negative Cowden/Cowden-like patients; downregulates KILLIN ~250-fold with normal PTEN transcription (Bennett, Mester & Eng 2010, JAMA 304:2724–31, PMID:21177507). Associated with ~3-fold higher breast cancer and >2-fold higher renal cancer prevalence than germline PTEN variants. Assigned OMIM #615107 (Cowden syndrome 4). - SDHB/*SDHD germline variants — 3 SDHB and 7 SDHD among 74 PTEN-negative Cowden-like individuals with elevated MnSOD (Ni et al. 2008, Am J Hum Genet 83:261–8, PMID:18678321). - Additional unexpected cancer-predisposition gene variants in PTEN-wildtype CS/BRRS (Yehia et al. 2018, PLoS Genet*).

Environmental risk factors

None established. BRRS is a monogenic Mendelian disorder with no documented environmental cause, no infectious trigger, and no lifestyle risk factor for the syndrome itself. This is a legitimate "not applicable" for the KB — do not fabricate.

Downstream cancer risk in carriers plausibly interacts with generic exposures (UV for the ~6% melanoma risk; diagnostic radiation given the tumor predisposition), but I found no BRRS/PHTS-specific gene–environment interaction study. Age is the dominant non-genetic modifier of expression — penetrance is strongly age-related, which is the reason BRRS and Cowden look like different diseases at different life stages.

Protective factors

No genetic protective variants or modifier alleles are documented. No dietary or lifestyle protective factor has been demonstrated. The only genuinely "protective" intervention is surveillance-based early detection, which is secondary prevention, not risk reduction.

Gene–environment interactions

Not characterized for BRRS. Report this as a knowledge gap — a discussions entry with kind: KNOWLEDGE_GAP is the honest treatment.

3. Phenotypes

BRRS-specific frequencies (best available source)

From the 2024 systematic review of 83 pediatric BRRS patients (PMID:39256443, Kapačinskaitė et al., Sci Rep 14, doi:10.1038/s41598-024-71991-2). These are frequencies among published pediatric case reports — publication bias is severe, so use qualitative FrequencyEnum bands rather than curating the exact percentages as population frequencies. Per docs/frequency-evidence-guidelines.md, the mapping below is my suggestion; when a number is soft, omit frequency: entirely.

Phenotype Reported frequency Suggested FrequencyEnum Candidate HP term (⚠️ verify)
Macrocephaly 77% (also 94% in PHTS overall per GeneReviews; often >5 SD above mean) VERY_FREQUENT HP:0000256 Macrocephaly
Developmental disorders (DD/ASD) 63% FREQUENT HP:0001263 Global developmental delay; HP:0000717 Autism
Pigmented genital macules (males) 75% (21/28 males) VERY_FREQUENT (males) ⚠️ no confident HP term — search "penile freckling"/"lentigines"; fallback HP:0007565
Skin manifestations (any) 64% FREQUENT HP:0000951 Abnormality of the skin
Lipomas >50% (18/33) FREQUENT HP:0012032 Lipoma
Gastrointestinal polyps 48% FREQUENT ⚠️ hamartomatous polyposis — verify HP:0004390 vs HP:0200008
Thyroid changes 36% OCCASIONAL–FREQUENT HP:0000820 Abnormal thyroid morphology
Hemangiomas 24% OCCASIONAL HP:0001028 Hemangioma
Arteriovenous malformations 18% OCCASIONAL HP:0100026 Arteriovenous malformation

Verbatim (PMID:39256443): "A total of 83 pediatric patients with BRRS were identified. The most common clinical findings were macrocephaly (77%) and developmental disorders (63%)."

Demographics from the same review: male predominance 60/83 (72%) — almost certainly an ascertainment artifact, since genital lentiginosis is a male-only diagnostic clue; median age 8 years; de novo variants in up to 48%.

Additional features (established in the older literature, frequencies less firm)

Neonatal macrosomia / large birth weight; accelerated linear growth in early childhood; muscular hypotonia and proximal myopathy (a genuinely BRRS-flavored feature, sometimes with lipid storage on muscle biopsy); joint hyperextensibility; pectus excavatum; scoliosis; café-au-lait macules; frontal bossing and dolichocephaly; downslanting palpebral fissures; Hashimoto thyroiditis (Gorlin et al. 1992, Am J Med Genet 44:307–14, PMID:1336932 — expanded the BRRS phenotype to include Hashimoto thyroiditis, present in 7 of their cases); high-arched palate; enlarged perivascular Virchow–Robin spaces on brain MRI.

Phenotype characteristics

  • Onset: congenital / neonatal for macrocephaly and macrosomia; infancy–early childhood for lipomas, vascular anomalies, and developmental concerns; peripubertal/adolescent (age ~10+) for genital lentiginosis; adult for the epithelial cancers.
  • Severity: highly variable, even within a single family carrying the identical variant. Lachlan et al. (2007, J Med Genet 44:579–85) concluded BRRS and CS are "one condition with variable expression and age-related penetrance" and argued it is "not helpful to split PTEN-related disorders into separate clinical syndromes."
  • Progression: the overgrowth features are largely stable/static after early childhood (macrocephaly does not progress; some lipomas enlarge). The tumor-predisposition component is progressive with age — new lesions and malignancies accrue lifelong. Vascular anomalies (PTEN hamartoma of soft tissue) are typically progressive and symptomatic, presenting with pain and swelling.
  • Quality-of-life impact: driven mostly by (a) neurodevelopment — intellectual disability, ASD, attention and processing-speed deficits; (b) pain and functional impairment from intramuscular vascular/soft-tissue hamartomas (one case in the Kurek series required amputation); (c) the psychological burden of lifelong cancer surveillance. I found no BRRS-specific EQ-5D/SF-36/PROMIS data — this is a real gap; the sirolimus vascular-anomaly experience reports "significant improvement in patient quality of life" without a validated instrument. Do not curate a QoL number.

Neurodevelopmental detail

PTEN is now recognized as one of the commonest monogenic causes of ASD with macrocephaly (~10% of ASD-plus-macrocephaly cases). GeneReviews: neurodevelopmental disorders in ~35% of children with PHTS; epilepsy 6–17% vs ~1% general population. Frazier et al. 2015 (Mol Psychiatry, PMID:25288137) found PTEN-ASD specifically associated with prominent white-matter abnormalities and "strong reductions in processing speed and working memory," with white-matter abnormality mediating the relationship between PTEN protein level and full-scale IQ. A 2024 systematic review of PHTS neurology (Dhawan, Baitamouni, Liu & Eng, Neurology 103(7):e209844, PMID:39250745) screened 1,996 articles and included 90 — but 54% were case reports, so the neurological evidence base is thin.

4. Genetic / Molecular Information

Causal gene

PTEN, 10q23.31, 9 exons, encoding a 403-amino-acid dual-specificity protein/lipid phosphatase. HGNC hgnc:9588 (note this repo's lowercase-prefix convention). OMIM *601728. UniProt P60484. A processed pseudogene, PTENP1 on chromosome 9, cross-amplifies during PCR and must be designed around — a practical testing caveat worth capturing.

Variant spectrum

  • Types: missense, nonsense, frameshift, splice-site, small indels, and whole-exon to whole-gene deletions. All classes are represented.
  • Exon 5 hotspot: "Nearly 40%" of PHTS variants fall in exon 5, which encodes the phosphatase (PTPase) core motif (HCXXGXXR, residues ~123–130). Marsh 1998 found 13/30 (43%) of Cowden variants in exon 5, with 7/30 (23%) inside the core motif itself — and notably none of the Bannayan–Zonana variants in the core motif.
  • Recurrent variants: c.388C>T (p.Arg130Ter), c.697C>T (p.Arg233Ter), c.1003C>T (p.Arg335Ter). R233X was seen in two unrelated Cowden families and one BZS family in the Marsh 1998 series — direct evidence for allelism.
  • Detection method yield (GeneReviews): coding-region sequencing ≤80%; deletion/duplication analysis 3–11%; promoter-region sequencing ~10% (do not skip the promoter).
  • Origin: germline for the syndrome; de novo in up to 48% of BRRS cases per the 2024 review — so a negative family history is common and does not argue against the diagnosis. Somatic PTEN loss is separately one of the most frequent events in sporadic cancer (glioblastoma, endometrial, prostate) — mechanistically informative but not part of the BRRS entry.
  • Population frequency: PTEN loss-of-function variants are extremely rare in gnomAD; the gene is strongly LoF-constrained. Recent unbiased biobank data suggest carriers are far commoner than the clinic-based estimate: an All of Us analysis found 55 P/LP carriers among 414,830 participants (~1 in 7,500), ~26-fold above historical estimates, with 43.5% having a cancer diagnosis (median age at first cancer 48 y). ⚠️ This is a medRxiv preprint (PMID:41480035, Dec 2025) — cite as preliminary, evidence_source: HUMAN_CLINICAL but flag preprint status. GeneReviews gives ~1 in 9,000 (All of Us) to 1 in 13,000 (UK Biobank).
  • Functional consequence: loss of function / haploinsufficiency is the dominant mechanism. Some missense alleles act as dominant negatives (the PTEN dimer means a catalytically dead monomer can poison the wild-type partner) — mechanistically important and worth a distinct pathophysiology node. Missense variants generally associate with milder phenotypes than truncating variants.

Genotype–phenotype correlations

From Marsh 1999 (BRRS-specific):

Verbatim (PMID:10400993): "Genotype-phenotype analyses within the BRR group suggested a number of correlations, including the association of PTEN mutation and cancer or breast fibroadenoma in any given CS, BRR or BRR/CS overlap family (P = 0.014), and, in particular, truncating mutations were associated with the presence of cancer and breast fibroadenoma in a given family (P = 0.024). Additionally, the presence of lipomas was correlated with the presence of PTEN mutation in BRR patients (P = 0.028)."

From Tan 2012 and GeneReviews (PHTS-wide): promoter variants → breast cancer; nonsense variants → colorectal cancer; frameshift variants overrepresented in thyroid cancer; missense variants overrepresented in ASD. Caveat for curation: these are cohort-level associations from ascertained series and should be curated with the association language, not as deterministic rules.

Verbatim (PMID:22252256): "Promoter mutations were associated with breast cancer, whereas colorectal cancer was associated with nonsense mutations."

Modifier genes

Not formally established. TTN (above) is a candidate contributing/modifying locus in PTEN-wildtype disease. Second somatic hits in PTEN and downstream PI3K-pathway lesions modulate lesion-level behavior but are not germline modifiers.

Epigenetics

  • Germline KLLN promoter hypermethylation (see §2) — a bona fide germline epigenetic etiology within the PHTS/Cowden-like spectrum, and one of the more elegant examples in human genetics: PTEN and KLLN share a bidirectional promoter, and the methylation silences KILLIN without touching PTEN transcription.
  • Somatic PTEN promoter methylation in tumors is a common second-hit mechanism.

Chromosomal abnormalities

Whole-gene and multi-exon PTEN deletions account for 3–11% of cases and are missed by sequencing alone — MLPA or CMA is required to complete the workup. Larger 10q23 contiguous-gene deletions spanning PTEN and BMPR1A produce a severe juvenile-polyposis-plus-BRRS phenotype in infancy and are worth curating as a distinct, more severe presentation.

5. Environmental Information

Not applicable as an etiology. No environmental factor, toxin, radiation exposure, occupational exposure, dietary factor, or infectious agent has been implicated in causing BRRS. There is no NCBI Taxon organism to associate.

The only defensible environmental content is downstream and generic: UV exposure as a modifiable contributor to the melanoma component (lifetime risk up to 6%, earliest reported age 3 years), which is why "sun protection" appears in the parent-education recommendations of the 2024 systematic review. Curate that as prevention guidance, not as an etiologic environmental factor.

6. Mechanism / Pathophysiology

The causal chain, upstream → downstream

Node 1 — Germline PTEN haploinsufficiency (MOLECULAR). One PTEN allele is inactivated in every cell from conception. Because PTEN is dose-sensitive, even 50% protein reduction perturbs signaling; tissue-specific second hits (somatic mutation, LOH, promoter methylation) deepen the loss focally and explain the patchy, hamartomatous distribution of lesions.

Node 2 — Loss of PIP₃ 3-phosphatase activity (MOLECULAR). PTEN's canonical function is dephosphorylating the 3-position of the inositol ring of phosphatidylinositol 3,4,5-trisphosphate (PIP₃), converting it back to PIP₂ — it is the direct antagonist of class I PI3K. Established by Maehama & Dixon 1998 (J Biol Chem 273:13375–8, PMID:9593664), who showed PTEN overexpression reduced insulin-induced PtdIns(3,4,5)P₃ in 293 cells and that purified recombinant PTEN dephosphorylates PIP₃ specifically at the 3-position. Marsh 1999 frames it in disease terms: "PTEN maps to 10q23 and encodes a dual specificity phosphatase, a substrate of which is phosphatidylinositol 3,4,5-triphosphate, a phospholipid in the phosphatidylinositol 3-kinase pathway."

Node 3 — Constitutive PI3K–AKT–mTORC1 pathway activation (CELLULAR). PIP₃ accumulates at the plasma membrane → PH-domain recruitment of AKT and PDK1 → AKT phosphorylation (Thr308/Ser473) → inhibition of TSC1/TSC2 → RHEB-GTP → mTORC1 activation → S6K1/4E-BP1 phosphorylation → increased cap-dependent translation, ribosome biogenesis, and cell mass. In parallel AKT phosphorylates and inactivates FOXO transcription factors, GSK3β, and BAD.

Node 4a — Increased cell growth, proliferation, and survival (CELLULAR). Net effect: increased cell size (not just number), increased proliferation, suppressed apoptosis, suppressed autophagy, loss of contact inhibition.

Node 4b — Cell-size / soma-size enlargement (CELLULAR). This is the specific mechanism behind macrocephaly and neuronal hypertrophy, and it's mTORC1-driven — which is why it is pharmacologically addressable.

Node 5 — Tissue-level hamartomatous overgrowth (TISSUE). Disorganized overgrowth of mature mesenchymal and epithelial elements — the definition of a hamartoma. Produces lipomas, GI polyps, PTEN hamartoma of soft tissue, and cerebellar dysplastic gangliocytoma.

Node 6 — Organism-level manifestations (ORGANISM). Macrocephaly, macrosomia, accelerated linear growth, ASD/DD, and lifelong tumor predisposition.

Parallel / non-canonical arms worth separate nodes

  • Protein-phosphatase and phosphatase-independent functions. PTEN also dephosphorylates protein substrates (e.g. FAK) and has scaffolding functions. The BRRS TTN work lands here: the p.Cys5096Arg variant produced "increased growth and lack of contact inhibition phenotype associated with increased levels of or phosphorylation of focal adhesion kinase (FAK)" — a PI3K-independent route to the same overgrowth output. Good candidate for an ALTERNATIVE or EMERGING mechanistic_hypotheses group.
  • Nuclear PTEN. PTEN shuttles to the nucleus, where it maintains chromosomal integrity and promotes RAD51-dependent DNA repair, independent of lipid phosphatase activity. Variants disrupting nuclear localization signals segregate with the ASD-predominant phenotype rather than the cancer phenotype (the basis of the Pten^m3m4^ mouse; §15). This is arguably the single most interesting mechanistic split in PHTS: where PTEN is, not just how much there is, determines whether you get autism or cancer. Curate as competing/complementary hypothesis groups.
  • Neurodevelopmental arm. PTEN loss in neurons → mTORC1 → increased soma size, exuberant dendritic arborization, aberrant synaptic connectivity, and (per the m3m4 mouse work) microglial activation with excessive synaptic pruning. Downstream: macrocephaly, white-matter abnormality, ASD, epilepsy.
  • Vascular arm. PI3K–AKT is a core endothelial/angiogenic pathway; PTEN loss produces the fast-flow vascular anomalies and intramuscular AVM-like lesions. Tan et al. 2007 (J Med Genet 44:594–602) found vascular anomalies in 14/26 (54%) of PTEN carriers, 57% multiple, 85% intramuscular on cross-sectional imaging, and 86% fast-flow.

Cellular processes, cell types, and compartments

Element Candidate term (⚠️ verify all)
PIP₃ 3-phosphatase activity GO:0016314 phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase activity
PI3K signaling GO:0014065 phosphatidylinositol 3-kinase signaling
PI3K/AKT signal transduction GO:0043491 phosphatidylinositol 3-kinase/protein kinase B signal transduction
TOR signaling GO:0031929 TOR signaling; GO:0038202 TORC1 signaling
Proliferation GO:0008284 positive regulation of cell population proliferation
Apoptosis suppression GO:0043066 negative regulation of apoptotic process
Autophagy GO:0006914 autophagy
Neuron projection development GO:0010975 regulation of neuron projection development
Organism growth GO:0035264 multicellular organism growth
Angiogenesis GO:0001525 angiogenesis
DNA repair (nuclear PTEN) GO:0006281 DNA repair
Adipocyte CL:0000136
Fibroblast CL:0000057
Endothelial cell CL:0000115
Neuron CL:0000540
Microglial cell CL:0000129
Purkinje cell / cerebellar granule cell CL:0000121 / CL:0000120
Thyroid follicular cell CL:0002258
Intestinal epithelial cell CL:0002563
Keratinocyte CL:0000312
Cytosol / plasma membrane / nucleus GO:0005829 / GO:0005886 / GO:0005634
PIP₃ CHEBI:16618 (1-phosphatidyl-1D-myo-inositol 3,4,5-trisphosphate) ⚠️

Metabolic, immune, and tissue-damage dimensions

  • Metabolic: AKT–mTORC1 activation shifts cells toward anabolic metabolism (glucose uptake, glycolysis, lipogenesis, protein synthesis). PTEN-carrier humans and Pten⁺/⁻ mice show enhanced insulin sensitivity — a notable, counterintuitive metabolic phenotype of the syndrome.
  • Immune: no autoimmunity is intrinsic to the mechanism, except that Hashimoto thyroiditis is overrepresented (Gorlin 1992: 7 cases) — mechanism unresolved, a legitimate knowledge gap. Microglial (innate CNS immune) activation is a key finding in the m3m4 mouse.
  • Tissue damage: BRRS is a disease of disorganized overgrowth, not of degeneration. There is no oxidative-stress/ischemia/fibrosis/necrosis core mechanism. The exceptions are secondary: mass effect and compression from lipomas and soft-tissue hamartomas, GI bleeding and intussusception from polyps, and high-output/steal physiology from fast-flow vascular lesions.

Molecular profiling

BRRS-specific omics are essentially absent. What exists is from PHTS/model systems: transcriptome and (phospho)proteome characterization of the cytoplasmic-predominant Pten^m3m4^ brain (npj Genom Med 2021), alternative-splicing landscape of the same model (Transl Psychiatry 2020), and a neural transcriptome study linking constitutional Pten dysfunction to idiopathic human ASD (PMID:25754085). Cortical transcriptomics in m3m4 showed upregulation of myeloid cell activation, myeloid cell migration, and phagocytosis pathways. No BRRS metabolomics, lipidomics, spatial transcriptomics, or single-cell atlas exists that I could find. Curate as gaps.

7. Anatomical Structures Affected

Organ level

Primary (directly affected by the germline lesion): - Brain (UBERON:0000955) — megalencephaly, enlarged perivascular spaces, white-matter abnormality, cortical malformations; cerebellum (UBERON:0002037) for dysplastic gangliocytoma / Lhermitte–Duclos disease - Skin and subcutis (UBERON:0002097) — lipomas, hemangiomas, café-au-lait macules, acral keratoses - Penis / external genitalia (UBERON:0000989) — pigmented macules of the glans, the BRRS-defining sign - Gastrointestinal tract — colon (UBERON:0001155), also ileum, duodenum, stomach, esophagus. Heald 2010 documented polyps throughout: "There were one to innumerable polyps in the colorectum, ileum, duodenum, stomach, and/or esophagus, with 24 subjects having both upper and lower GI polyps." - Skeletal muscle (UBERON:0001134) — intramuscular PTEN hamartoma of soft tissue; proximal myopathy - Adipose tissue (UBERON:0001013) — lipomatous overgrowth - Thyroid gland (UBERON:0002046) — goiter, nodules, Hashimoto thyroiditis, differentiated carcinoma - Blood vessels (UBERON:0001981) — fast-flow malformations, AVMs

Secondary / later-emerging (the PHTS cancer spectrum): breast (UBERON:0000310), endometrium (UBERON:0001295), kidney (UBERON:0002113), skin (melanoma), colon (carcinoma).

Body systems: nervous, integumentary, digestive, endocrine, musculoskeletal, cardiovascular (vascular malformations), reproductive.

Tissue, cell, and subcellular level

Fundamentally a disease of mesenchymal + epithelial tissues in combination. Kurek's definition of PTEN hamartoma of soft tissue is the clearest tissue-level statement available:

Verbatim (PMID:22446940, Kurek et al. 2012, Am J Surg Pathol 36:671–87): "We designate this disorganized overgrowth of essentially mesenchymal elements as PTEN hamartoma of soft tissue."

Its components, per the same abstract: "(1) a variable admixture of mature adipocytic and dense and/or myxoid fibrous tissues (50% to 90% of surface area); (2) a vascular component (10% to 50% of surface area)... (3) lymphoid follicles (50%); (4) foci of bone (20%); and (5) hypertrophic nerves with 'onion bulb' proliferation of periaxonal spindled cells (9%)."

Subcellular: plasma membrane (PIP₃ pool, PTEN's site of action), cytosol, and nucleus — with the nuclear/cytoplasmic partition being mechanistically load-bearing (§6).

Lateralization: lesions are multifocal and asymmetric, not systematically lateralized. Kurek: lesions "most often located in the lower extremity," 20% multifocal, occasionally involving contiguous muscles. Macrocephaly is symmetric.

8. Temporal Development

  • Onset: congenital. Macrocephaly is present at birth or emerges in the first two years — "nearly all children by age 2" per the German pediatric guideline. Neonatal macrosomia is common. Onset pattern is insidious/chronic, not acute.
  • Lesion timing: Kurek — soft-tissue hamartomas "manifested by 15 years of age, normally with pain and swelling." Genital lentiginosis typically appears around/after puberty, which is why it is a poor sign in toddlers. GI polyps present in ~25–30% of pediatric cases (GeneReviews) but 93% of endoscoped adult carriers.
  • Stages: there is no formal staging system. A useful three-phase framing for the KB: (i) congenital/infantile overgrowth phase (macrocephaly, macrosomia, hypotonia, early lipomas/vascular lesions); (ii) childhood neurodevelopmental phase (DD, ASD, epilepsy) with emerging polyps and thyroid nodules; (iii) adult neoplastic phase (breast, thyroid, endometrial, renal, colorectal cancer, melanoma).
  • Progression rate: slow and variable. The overgrowth features are largely static; the neoplastic risk is cumulative and age-dependent.
  • Course: chronic, lifelong, progressive with respect to tumor risk. Not relapsing-remitting, not episodic. No spontaneous remission of the syndrome. Individual lesions may regress with mTOR-inhibitor therapy (see §12).
  • Critical periods: early childhood for neurodevelopmental intervention; age 10–12 for the start of thyroid surveillance (thyroid cancer reported as young as age 4–7); age ~30 for breast surveillance; age 35 for colonoscopy. Genetic diagnosis at any age is the intervention that unlocks all the rest.

9. Inheritance and Population

Epidemiology

  • Prevalence: unknown/not documented. Orphanet does not assign a prevalence class to ORPHA:109. A widely circulated figure of ~1 per 200,000 appears in secondary sources without a strong primary citation — do not curate it as a sourced prevalence; use prevalence_class: NOT_YET_DOCUMENTED or ULTRA_RARE with measure_type: UNKNOWN.
  • The molecularly-defined denominator is far larger than the clinically-defined one. GeneReviews cites ~1 in 9,000 (All of Us) to 1 in 13,000 (UK Biobank) for germline PTEN P/LP carriers; the 2025 All of Us preprint reports 1 in 7,500 (55/414,830), ~26-fold above historical estimates. These are PHTS-wide, not BRRS, and describe carriers, not diagnosed patients. If you curate them, do it on a PHTS/Cowden entry or with an explicit note; measure_type: CARRIER_FREQUENCY is arguably the honest classification.
  • Incidence: no reliable estimate exists.

Inheritance

  • Pattern: autosomal dominant (HP:0000006). PTEN is MONDO:0007924's canonical causal gene.
  • De novo rate: up to 48% of BRRS cases (2024 systematic review) — high, consistent with a severe pediatric-onset presentation.
  • Penetrance: essentially complete for some feature (macrocephaly is near-obligate) but strongly age-related and organ-specific for the tumor phenotypes. Unbiased biobank data suggest penetrance is considerably lower than clinic-ascertained estimates — a live and important controversy. Curate the clinic-based lifetime risks with an explicit ascertainment caveat.
  • Expressivity: markedly variable, including within families sharing an identical variant. This is the central clinical-genetics message of Lachlan 2007.
  • Anticipation: not a feature (no repeat expansion mechanism).
  • Germline mosaicism: reported in PTEN and relevant to recurrence counseling in apparently-de-novo families, but rare and not well quantified. Somatic mosaicism is a recognized cause of segmental/atypical presentations and of negative blood-based testing in a clinically convincing patient — this matters for diagnostics.
  • Founder effects / consanguinity / carrier frequency: none — irrelevant for a dominant de-novo-prone condition. No population-specific founder variant is described.

Population demographics

  • Ethnic/geographic: no population is over-represented; cases are reported worldwide with no endemic distribution.
  • Sex ratio: published pediatric BRRS cases run ~72% male (60/83), but this is very likely ascertainment bias from the male-specific genital-lentiginosis sign. The underlying autosomal-dominant inheritance predicts 1:1. Curate the 1:1 expectation and note the reporting skew.
  • Age distribution: BRRS as a label is applied predominantly in childhood (median age 8 in the review); the same genotype in adults is usually labeled Cowden syndrome.

10. Diagnostics

Clinical evaluation

  • Occipitofrontal circumference — the highest-yield single measurement; macrocephaly is often >5 SD above mean.
  • Genital examination in males for pigmented macules of the glans penis (75% of male cases) — pathognomonic-adjacent and free.
  • Dermatologic exam for lipomas, hemangiomas, café-au-lait macules, trichilemmomas/acral keratoses (the latter more Cowden-flavored).
  • Developmental/neurobehavioral assessment, including formal ASD evaluation.

Imaging and functional testing

  • Brain MRI — megalencephaly, enlarged Virchow–Robin spaces, white-matter changes; the cerebellar "tiger-striped" appearance of Lhermitte–Duclos disease. A dedicated BRRS MRI series exists (Bhargava et al., AJNR 35:402, PMID:23907246).
  • MRI for soft-tissue/vascular lesions — Kurek: "an infiltrative soft tissue lesion involving the muscle, fascia, and subcutis with frequently enlarged, serpiginous vessels, small arteriovenous fistulae with disproportionately dilated draining veins, and a prominent adipocytic component." Distinguishing PHOST from a true AVM matters because it changes management.
  • Thyroid ultrasound — the pediatric surveillance workhorse.
  • Esophagogastroduodenoscopy + colonoscopy — mixed polyposis, upper and lower.
  • EEG where seizures are suspected (epilepsy 6–17%).

Biopsy and pathology

  • GI polyps in PHTS are a mixed polyposis — this is a frequent diagnostic pitfall, because people expect pure hamartomas. Heald 2010: "Of the 64, half had hyperplastic polyps" and the conclusion — "PTEN-associated CS should be considered a mixed polyp syndrome, with hyperplastic polyps most prevalent, with a risk of early onset colorectal cancer." Hamartomatous, ganglioneuromatous, juvenile, inflammatory, hyperplastic, and adenomatous polyps all occur.
  • PTEN hamartoma of soft tissue has the distinctive histology quoted in §7, and per Kurek "its identification should prompt a thorough investigation for PHTS" — i.e. the pathologist can make the syndromic diagnosis.
  • Immunohistochemistry for PTEN loss in lesional tissue is supportive.

Genetic testing (the definitive test)

Since PHTS has no clinical diagnostic criteria, molecular confirmation is the diagnosis. Recommended approach:

  1. Single-gene PTEN testing — full coding sequence plus the promoter region (~10% of variants are promoter). Design around the PTENP1 pseudogene.
  2. Deletion/duplication analysis (MLPA) — mandatory adjunct; 3–11% of variants.
  3. Multigene hamartomatous-polyposis / hereditary-cancer panel where the phenotype is ambiguous (differentiating from STK11, SMAD4, BMPR1A, AKT1, PIK3CA).
  4. Chromosomal microarray — detects the 10q23 contiguous-gene deletions involving PTEN + BMPR1A, and is often the first test in a child presenting with DD/macrocephaly.
  5. WES/WGS — reasonable in the undiagnosed-DD pathway; also the route by which TTN was implicated in PTEN-wildtype BRRS.
  6. Not applicable: karyotype (too coarse), FISH (superseded by MLPA/CMA), mtDNA testing, repeat-expansion testing.
  7. If PTEN-negative but clinically classic: consider KLLN germline methylation testing, SDHB/SDHD, and mosaicism (test lesional tissue, not just blood).

Omics-based diagnostics

Not established for BRRS. No validated RNA-seq, proteomic, metabolomic, epigenomic (other than the KLLN methylation assay), or liquid-biopsy diagnostic exists. A methylated KILLIN/PTEN plasma assay has been explored for thyroid/breast cancer detection but is not a clinical diagnostic for BRRS.

Clinical criteria and differential diagnosis

The International Cowden Consortium operational criteria (and the Cleveland Clinic PTEN risk calculator, Tan et al. 2011) select who to test; they do not diagnose PHTS. Historical BRRS clinical criteria required macrocephaly plus two of: hamartomatous polyps, lipomas, genital lentiginosis.

Differential diagnosis:

Condition Distinguishing features
Cowden syndrome (MONDO:0016063) Same gene, same disease — adult mucocutaneous/cancer presentation. Distinguish by age and presentation, not biology
Peutz–Jeghers (STK11) Perioral/buccal mucocutaneous pigmentation (not genital-only); polyps show characteristic smooth-muscle arborization
Juvenile polyposis (SMAD4, BMPR1A) Juvenile polyps; HHT overlap if SMAD4; no macrocephaly/lipomas
Proteus syndrome (AKT1 mosaic) Progressive, asymmetric, distorting overgrowth; cerebriform connective tissue nevus
PIK3CA-related overgrowth (PROS/CLOVES) Mosaic, segmental; same pathway, different node
Neurofibromatosis type 1 Café-au-lait + neurofibromas + Lisch nodules; macrocephaly overlaps — a genuine clinical trap
Simpson–Golabi–Behmel, Sotos, Weaver Other overgrowth syndromes; distinguish by facies, skeletal findings, and gene
Isolated benign macrocephaly The commonest real-world alternative in a well child

Screening of asymptomatic individuals

Cascade testing of at-risk first-degree relatives is the key intervention, and given up-to-48% de novo rates, parental testing is essential for recurrence counseling. There is no newborn screening and no population carrier screening for PTEN. Prenatal/preimplantation testing is technically available once a familial variant is known.

11. Outcome / Prognosis

  • Life expectancy: not formally quantified for BRRS. With surveillance, life expectancy is thought to approach normal; the drivers of mortality are the malignancies, not the overgrowth. Do not curate a survival number — I found none that is BRRS-specific and defensible.
  • Cancer risk (PHTS-wide, from clinic-ascertained cohorts):

Verbatim (PMID:22252256, Tan et al. 2012, Clin Cancer Res 18:400–7): "Elevated SIRs were found for carcinomas of the breast [25.4, 95% confidence interval (CI), 19.8-32.0], thyroid (51.1, 38.1-67.1), endometrium (42.9, 28.1-62.8), colorectum (10.3, 5.6-17.4), kidney (30.6, 17.8-49.4), and melanoma (8.5, 4.1-15.6). Estimated lifetime risks were, respectively, 85.2% (95% CI, 71.4%-99.1%), 35.2% (19.7%-50.7%), 28.2% (17.1%-39.3%), 9.0% (3.8%-14.1%), 33.6% (10.4%-56.9%), and 6% (1.6%-9.4%)."

GeneReviews gives comparable ranges (breast 85–91%, thyroid 33–35%, endometrial 28–48%, renal 30–35%, colorectal 17%, melanoma up to 6%) plus soft-tissue sarcoma SIR 10.7 (95% CI 3.9–23.7), median age 46. Later European work (Hendricks et al., Clin Genet 2021; JNCI 2023) gives lower estimates — breast 54–76%, endometrial 6–22%, thyroid 9–21% — reflecting less-biased ascertainment. Curate the range with both anchors and an explicit ascertainment caveat; a single point estimate here would be misleading. - Colorectal cancer, early onset: Heald 2010 — "Nine (13%) subjects had colorectal cancer, all younger than the age of 50. The adjusted standardized incidence ratio was 224.1 (95% confidence interval, 109.3-411.3; P < .0001)." - Morbidity and disability: dominated by neurodevelopmental outcome (intellectual disability, ASD, epilepsy) and by pain/functional loss from soft-tissue and vascular lesions — Kurek reported resected specimens 1.2–25 cm, with amputation required in one patient. GI morbidity from bleeding, anemia, intussusception, and repeated polypectomy. - Complications: early-onset colorectal carcinoma; differentiated thyroid carcinoma (reported as young as 4–7 years); Lhermitte–Duclos disease with mass effect/hydrocephalus; hemorrhage and high-output physiology from fast-flow vascular lesions; recurrent surgical morbidity. - Recovery potential: the germline lesion is not reversible. Individual lesions respond to surgery and, partially, to mTOR inhibition. Developmental gains occur with early intervention. Surveillance is the single largest determinant of outcome. - Prognostic factors: variant type (truncating → higher cancer risk per Marsh 1999; promoter → breast; nonsense → colorectal); age; adherence to surveillance; presence and extent of vascular/soft-tissue hamartomas; severity of neurodevelopmental impairment. No validated prognostic biomarker exists.

12. Treatment

There is no disease-modifying or curative therapy. Management is surveillance + symptom-directed intervention + genetic counseling. The 2024 systematic review is blunt about it: "As targeted treatment is still lacking, symptom relief and long-term surveillance remain the main management strategies."

Surgical / interventional (the mainstay)

Per the 2024 review, surgery was the treatment of choice, described in 19 of 33 articles: - Lipoma excision — for pain, disfigurement, compression. treatment_term: NCIT:C15329 Surgical Procedure ⚠️ - Endoscopic polypectomy — for bleeding, obstruction, dysplasia. ⚠️ verify NCIT term for polypectomy - Thyroidectomy — 4 pediatric cases in the review; prophylactic thyroidectomy is debated in PHTS and is not standard, unlike in MEN2. NCIT:C15289-adjacent ⚠️ - Vascular anomaly management — embolization, sclerotherapy, or resection. Because PHOST is not a true AVM, embolization outcomes are less predictable than for classic AVM. - Resection of Lhermitte–Duclos lesions where symptomatic.

Pharmacotherapy — mTOR inhibitors

Mechanistically the obvious move: PTEN loss → mTORC1 hyperactivation → inhibit mTOR. Results so far are mixed, and this nuance must survive into the KB.

Sirolimus (rapamycin) — CHEBI:9168 ⚠️; therapeutic_modality: SMALL_MOLECULE; treatment_term: NCIT:C15986 Pharmacotherapy. - Komiya et al. 2019 (The Oncologist 24:1510, doi:10.1634/theoncologist.2019-0514): first human interventional study in Cowden/PTEN patients; 18 patients, 16 families; 56-day course. Well tolerated; regression of skin and GI lesions by dermoscopy/endoscopy, improved cerebellar function score at 1 month, and suppressed mTOR signaling in surrogate tissue. Pilot-scale — no efficacy claim. - Open-label sirolimus 2 mg daily × 1 year for colon polyposis in PHTS (NCT04094675, Nov 2018 – Jun 2024) — published in Clin Transl Gastroenterol. - Case-level use in pediatric BRRS for AVM: the 2024 review notes one pediatric case, with AVM size reduction and symptom relief within 6 months. - Sirolimus for PHTS vascular anomalies: well tolerated, patient-reported QoL improvement (n=6).

Everolimus — CHEBI:68478 ⚠️. The one properly controlled trial is negative for its primary endpoint: - Srivastava et al. 2022 (Hum Mol Genet 31:3393–404, PMID:35594551): 6-month phase II, randomized, double-blind, placebo-controlled, everolimus 4.5 mg/m², ages 5–45, n=46 (24 everolimus / 22 placebo). Primary neurocognitive composite: no group difference (Cohen's d = −0.10, p = 0.518); GI adverse events significantly more common on everolimus (p < 0.001). - Curate this honestly. An entry that lists "mTOR inhibitors" as treatment for PHTS neurocognitive symptoms without the negative RCT would be misleading. It is a good candidate for an evidence item with supports: REFUTE or PARTIAL.

Targeted / advanced therapeutics

None approved. No gene therapy, gene editing, cell therapy, RNA-based therapy, or immunotherapy exists for BRRS. PI3K/AKT inhibitors are conceptually attractive and used in PIK3CA-related overgrowth (alpelisib) but are not established in PHTS. Do not extrapolate.

Pharmacogenomics

No PHTS-specific pharmacogenomic guidance. Standard CPIC guidance applies to any drugs used for the cancers that arise.

Supportive, rehabilitative, and counseling

  • Early intervention, physical therapy (NCIT:C15302), occupational therapy, speech therapy — for hypotonia, motor delay, and language delay. therapeutic_modality: BEHAVIORAL.
  • ASD-specific behavioral intervention and educational support.
  • Antiseizure medication where epilepsy is present.
  • Genetic counseling (NCIT:C15240) — recurrence risk 50% per offspring; parental testing given the high de novo rate; discussion of prenatal/PGT options; cascade testing of relatives.
  • Multidisciplinary care is the explicit recommendation of the 2024 review: "periodic multidisciplinary care that should be individualized to fit every patient's needs."

Treatment strategy

Individualized, lesion-directed, and surveillance-anchored. No treatment algorithm or decision tree is standardized. No combination-therapy regimen exists (so regimen_term is not applicable here).

13. Prevention

  • Primary prevention: not possible. The disorder is germline and congenital. No vaccination, no modifiable exposure, no risk-factor modification prevents BRRS. The only true primary prevention available is reproductive — preimplantation genetic testing or prenatal diagnosis once a familial variant is identified, which is a family-planning decision requiring genetic counseling, not a public-health intervention.
  • Secondary prevention: this is where essentially all the benefit lives. Surveillance recommendations (synthesizing GeneReviews, the 2020 European guideline (Tischkowitz et al., Eur J Hum Genet 28:1387–93, PMC7608293), the 2025 pediatric update (Clin Cancer Res 31(2):234), and the German pediatric guideline):
Target Recommendation
Thyroid Annual clinical exam + thyroid ultrasound from age 12 (some centers from age 10; every 2–3 y under age 7 if no nodules). Cancer reported as young as 4–7 y
Breast Monthly self-exam from 18; clinical exam q6–12 mo from 25; annual mammogram + breast MRI from 30
Endometrium Assessment q1–2 y from age 30–35; educate about abnormal bleeding
Colon Colonoscopy from age 35, q5 y (sooner/more often if polyp burden is high — and note the early-onset CRC signal)
Kidney Renal imaging q1–2 y from age 40
Skin Annual comprehensive dermatologic exam; sun protection education
Brain MRI as clinically indicated; q3–12 mo if Lhermitte–Duclos present
Pediatric extras Annual dermatologic exam; annual abdominal ultrasound; testicular ultrasound from ~age 10; ongoing psychomotor/neurodevelopmental assessment (German guideline)

Yield data exist and are modest but real: thyroid ultrasound surveillance detected DTC in 2/43 (4.65%) of PHTS patients before age 18 in one expertise centre.

  • Tertiary prevention: management of polyp burden to prevent CRC; management of vascular lesions to prevent hemorrhage; neurodevelopmental support to maximize function.
  • Risk stratification: the Cleveland Clinic PTEN score (Tan et al. 2011) identifies who should be tested; variant type provides coarse organ-risk stratification.
  • Immunization, public-health, and environmental interventions: not applicable.

14. Other Species / Natural Disease

  • Naturally occurring BRRS in other species: none reported. I found no OMIA entry for a spontaneous PTEN hamartoma syndrome in companion animals or wildlife, and no veterinary breed predisposition. There is no VBO breed to assign.
  • Zoonotic potential / cross-species transmission: not applicable — it's a germline genetic disorder.
  • PTEN orthologs are deeply conserved, which is what makes the modeling work: mouse Pten (NCBI Gene 19211, NCBITaxon:10090), rat Pten, zebrafish has two paralogs ptena/ptenb (NCBITaxon:7955), Drosophila Pten (NCBITaxon:7227), C. elegans daf-18 (NCBITaxon:6239). The daf-18 connection is a nice piece of comparative biology: the insulin/IGF-1–PI3K–DAF-16/FOXO axis controlling dauer formation and lifespan in worms is the same pathway that, dysregulated in humans, produces hamartomas. Conserved mechanism, wildly different phenotypic readout.
  • Comparative pathology: somatic PTEN loss is a recurrent event in spontaneous canine and feline tumors (canine osteosarcoma, melanoma, glioma), making dogs an incidental comparative-oncology resource — but that is somatic tumor biology, not the germline syndrome.

15. Model Organisms

Mouse (NCBITaxon:10090) — the workhorse

Model Design Phenotype Citation
Pten⁺/⁻ (constitutive het) Germline heterozygous null — the direct genocopy of human PHTS Multi-organ hyperplasia and neoplasia (thyroid, endometrium, GI, lymphoid); increased insulin sensitivity. Homozygous null is embryonic lethal, establishing the dominant/haploinsufficient mechanism Di Cristofano et al. 1998 Nat Genet; Podsypanina et al. 1999 PNAS
Nse-Cre / GFAP-Cre conditional brain Pten KO Neuron- or glia-restricted deletion "Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease" — a near-exact recapitulation of the human cerebellar phenotype Backman et al. 2001 Nat Genet 29:396–403, PMID:11726927; Kwon et al. 2001, PMID:11726928
Nse-Cre Pten KO (cortex/hippocampus) Deletion in limited differentiated neuronal populations Abnormal social interaction, exaggerated response to sensory stimuli, macrocephaly, increased dendritic arborization — the founding PTEN autism model Kwon et al. 2006 Neuron 50:377–88, PMID:16675393
Pten^m3m4^ (knock-in) Disrupts 2 of 4 putative nuclear localization signals → cytoplasm-predominant PTEN with nuclear depletion; normal total protein Macrocephaly from megencephaly, neuronal soma hypertrophy, gliosis, autism-like behavior; microglial activation with enhanced synaptic pruning; cortical upregulation of myeloid activation/migration/phagocytosis pathways Sarn et al. 2020 Mol Psychiatry, doi:10.1038/s41380-020-0681-0
Nuclear-predominant Pten model Complementary partition mutant Impaired social and perseverative behavior, microglial activation, increased oxytocinergic activity Mol Autism 2021, doi:10.1186/s13229-021-00448-4
Pten^m3m4^ multi-omics — Transcriptome/(phospho)proteome and alternative-splicing characterization of the autism-like brain npj Genom Med 2021; Transl Psychiatry 2020

Why the m3m4 model matters for this entry: it demonstrates that subcellular mislocalization of PTEN — with normal expression level — is sufficient to produce the neurodevelopmental arm of PHTS. That's a genuine mechanistic dissociation between the ASD phenotype and the cancer phenotype, and it maps directly onto the human genotype–phenotype observation that missense variants are overrepresented in ASD. It is the strongest argument for curating the neurodevelopmental and neoplastic arms as separate pathophysiology branches.

Other systems

  • Zebrafish (NCBITaxon:7955): ptena/ptenb double mutants are embryonic lethal with hyperbranched vasculature; single mutants are viable and tumor-prone — a useful vascular/angiogenesis model given the BRRS vascular phenotype.
  • Drosophila (NCBITaxon:7227): Pten mutants show classic cell-size and organ-size overgrowth; the system where the PI3K–TOR growth-control logic was largely worked out.
  • C. elegans (NCBITaxon:6239): daf-18, the insulin/IGF-1–DAF-16 axis.
  • Cell and in vitro: patient-derived fibroblasts and LCLs; patient iPSC-derived neurons and cortical organoids show increased soma size, altered proliferation, and synaptic phenotypes, and are the most translationally relevant human system currently available; CRISPR-edited isogenic lines (the route used for the TTN p.Cys5096Arg functional work). MorPhiC has not, to my knowledge, targeted PTEN — worth checking morphic.bio before asserting either way.

Recapitulation and limitations

Recapitulates well: macrocephaly/megalencephaly, neuronal soma enlargement, Lhermitte–Duclos-like cerebellar pathology, ASD-like social deficits, seizures, multi-organ tumor predisposition, enhanced insulin sensitivity.

Does NOT recapitulate: genital lentiginosis (no analog), the human GI mixed-polyp spectrum in its full form, the specific human cancer-organ distribution (mouse tumor spectrum skews differently — thyroid/endometrial/lymphoid rather than breast-dominant), PTEN hamartoma of soft tissue as a defined entity, and the human developmental/cognitive profile in any fine-grained way. Mouse background strain strongly modifies tumor spectrum. Any curated evidence item drawn from these should carry evidence_source: MODEL_ORGANISM and must not be the sole support for a human phenotype — and given the m3m4 findings are load-bearing for the ASD mechanism but unconfirmed in human tissue, a discussions entry with kind: HUMAN_MODEL_MISMATCH is warranted rather than a plain KNOWLEDGE_GAP.

Model databases

MGI (mouse), Alliance of Genome Resources, IMPC/KOMP, IMSR/JAX for strain availability, ZFIN, FlyBase, WormBase, Cellosaurus for lines.

Appendix A — Suggested mechanistic_hypotheses and discussions

Things I'd flag as genuinely unsettled, worth curating as structured discussion rather than prose:

  1. nuclear_vs_cytoplasmic_pten (competing hypothesis groups). Whether the ASD/neurodevelopmental arm is driven by loss of nuclear PTEN function (DNA repair, m3m4 evidence) versus by cytoplasmic PIP₃/mTORC1 excess. status: EMERGING. Attaches to the neurodevelopmental branch.
  2. ttn_as_brrs_gene — KNOWLEDGE_GAP / EMERGING. TTN enrichment in PTEN-wildtype BRRS is statistically modest (OR 2.2–2.7, p ≈ 0.02–0.05, single lab, no replication cohort published that I found). Do not curate TTN as causal.
  3. phts_penetrance_ascertainment — KNOWLEDGE_GAP. Clinic-ascertained lifetime cancer risks (breast 85%) versus biobank-derived risks (54–76%, and much lower overall penetrance in All of Us/UK Biobank) differ enough to change clinical advice. Unresolved.
  4. mtor_inhibition_efficacy — KNOWLEDGE_GAP. Sirolimus pilots are positive on biomarkers and lesions; the only randomized everolimus trial missed its neurocognitive primary endpoint. Whether mTOR inhibition helps any PHTS outcome durably is open.
  5. hashimoto_thyroiditis_mechanism — KNOWLEDGE_GAP. Autoimmune thyroiditis is overrepresented since Gorlin 1992; no mechanism connects PTEN loss to thyroid autoimmunity.
  6. brrs_cowden_entity_boundary. Worth an explicit note: this KB models BRRS and Cowden as separate entries while the literature treats them as one disease. Consider a Grouping over the PHTS entries with grouping_basis: [SHARED_MECHANISM, CLINICAL_CONVENTION] and a grouping_rationale that records exactly this lump/split tension — a NECESSARY HAS_GENE criterion on PTEN would make the boundary auditable.

Appendix B — Suggested conforms_to module targets

Check these against kb/modules/ before asserting: - The PI3K–AKT–mTOR overgrowth logic here has no dedicated module yet — BRRS/PHTS would be a strong flagship if one is created (candidate: pi3k_akt_mtor_overgrowth). - genome_instability_mutation — the nuclear-PTEN/RAD51 arm plausibly conforms. - sustaining_proliferative_signaling — constitutive PI3K–AKT mitogenic signaling is exactly this hallmark node. - evading_growth_suppressors — PTEN is a canonical tumor suppressor; the two-hit/haploinsufficiency logic fits. - tumor_angiogenesis — for the vascular malformation arm, though the fit is imperfect (these are malformations, not tumor neovasculature).

References (with PMIDs)

Verbatim abstract text retrieved and usable as evidence snippets (still run just fetch-reference + just validate-references):

  • PMID:10400993 — Marsh DJ, Kum JB, Lunetta KL, et al. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet. 1999;8(8):1461-72. doi:10.1093/hmg/8.8.1461
  • PMID:9467011 — Marsh DJ, Coulon V, Lunetta KL, et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome. Hum Mol Genet. 1998;7(3):507-15. doi:10.1093/hmg/7.3.507
  • PMID:22252256 — Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 2012;18(2):400-7.
  • PMID:20600018 — Heald B, Mester J, Rybicki L, Orloff MS, Burke CA, Eng C. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology. 2010;139(6):1927-33.
  • PMID:22446940 — Kurek KC, Howard E, Tennant LB, et al. PTEN hamartoma of soft tissue: a distinctive lesion in PTEN syndromes. Am J Surg Pathol. 2012;36(5):671-87.
  • PMID:29263846 — Yehia L, Ni Y, Eng C. Germline TTN variants are enriched in PTEN-wildtype Bannayan-Riley-Ruvalcaba syndrome. npj Genom Med. 2017;2:37. doi:10.1038/s41525-017-0039-y
  • PMID:31609537 — Macken WL, Tischkowitz M, Lachlan KL. PTEN hamartoma tumor syndrome in childhood: A review of the clinical literature. Am J Med Genet C. 2019.
  • PMID:39256443 — Kapačinskaitė M, Stratica N, Adomaitienė I, Rascon J, Vaišnytė B. A systematic review of Bannayan-Riley-Ruvalcaba syndrome. Sci Rep. 2024;14. doi:10.1038/s41598-024-71991-2

Cited but abstract not independently retrieved verbatim — verify before quoting:

  • PMID:9241266 — Marsh DJ, et al. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet. 1997;16(4):333-4. ⚠️ Letter — no abstract exists. Cannot supply a snippet.
  • PMID:11332402 — Parisi MA, et al. The spectrum and evolution of phenotypic findings in PTEN mutation positive cases of Bannayan-Riley-Ruvalcaba syndrome. J Med Genet. 2001;38(1):52-8. ⚠️ No abstractText in Europe PMC; use PMC1734718 full text.
  • PMID:1336932 — Gorlin RJ, et al. Bannayan-Riley-Ruvalcaba syndrome. Am J Med Genet. 1992;44(3):307-14.
  • PMID:9593664 — Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998;273(22):13375-8.
  • PMID:12938083 — Eng C. PTEN: one gene, many syndromes. Hum Mutat. 2003.
  • PMID:11726927 / PMID:11726928 — Backman SA et al.; Kwon CH et al. Nat Genet. 2001.
  • PMID:16675393 — Kwon CH, Luikart BW, Powell CM, et al. Pten regulates neuronal arborization and social interaction in mice. Neuron. 2006;50(3):377-88.
  • PMID:18678321 — Ni Y, Zbuk KM, Sadler T, et al. Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes. Am J Hum Genet. 2008;83(2):261-8.
  • PMID:21177507 — Bennett KL, Mester J, Eng C. Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome. JAMA. 2010;304(24):2724-31.
  • PMID:25288137 — Frazier TW, et al. Molecular and phenotypic abnormalities in individuals with germline heterozygous PTEN mutations and autism. Mol Psychiatry. 2015.
  • PMID:25754085 — Neural transcriptome of constitutional Pten dysfunction in mice and its relevance to human idiopathic ASD.
  • PMID:23907246 — Bhargava R, et al. Bannayan-Riley-Ruvalcaba syndrome: MRI neuroimaging features in a series of 7 patients. AJNR. 2014;35(2):402.
  • PMID:35594551 — Srivastava S, et al. A randomized controlled trial of everolimus for neurocognitive symptoms in PTEN hamartoma tumor syndrome. Hum Mol Genet. 2022;31(20):3393-404.
  • PMID:39250745 — Dhawan A, Baitamouni S, Liu D, Eng C. Clinical Neurologic Features and Evaluation of PTEN Hamartoma Tumor Syndrome: A Systematic Review. Neurology. 2024;103(7):e209844.
  • PMID:31433955 — Yehia L, Keel E, Eng C. The Clinical Spectrum of PTEN Mutations. Annu Rev Med. 2020.
  • Tischkowitz M, Colas C, Pouwels S, et al. Cancer Surveillance Guideline for individuals with PTEN hamartoma tumour syndrome. Eur J Hum Genet. 2020;28:1387-93. (PMC7608293)
  • Komiya T, Blumenthal GM, DeChowdhury R, et al. A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN. The Oncologist. 2019;24(12):1510. (PMC6975943)
  • Hendricks LAJ, et al. A review on age-related cancer risks in PTEN hamartoma tumor syndrome. Clin Genet. 2021. (PMC7839546) · Cancer risks by sex and variant type in PHTS. JNCI. 2023.
  • Update on Pediatric Surveillance Recommendations for PTEN Hamartoma Tumor Syndrome, DICER1-Related Tumor Predisposition, and Tuberous Sclerosis Complex. Clin Cancer Res. 2025;31(2):234.
  • PMID:41480035 — Population-based Characterization of PTEN Hamartoma Tumor Syndrome. medRxiv preprint, Dec 2025 — cite as preliminary.
  • Sarn N, et al. Cytoplasmic-predominant Pten increases microglial activation and synaptic pruning in a murine model with autism-like phenotype. Mol Psychiatry. 2021. (PMC8159731)
  • GeneReviews: PTEN Hamartoma Tumor Syndrome. NCBI Bookshelf NBK1488. (PMID:20301661)

Sources: